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The predominant mechanism of herpes simplex virus type 1 (HSV-1) entry into permissive cells 
involves initial virus attachment to the cells by the interaction of envelope glycoproteins gC and 
gB with cell surface glycosaminoglycans (GAGs), binding of envelope glycoprotein D to one of 
several dissimilar co-receptors, and fusion of the virus envelope with the cell membrane 
requiring the combined essential functions of glycoproteins gD, gB and gH/gL. The binding of 
gD to its cognate receptor appears to result in emission of an activating signal to the fusion 
apparatus which minimally consists of the other essential glycoproteins. To gain a better 
understanding of gD’s involvement in the fusion-activating process, we took the approach of 
separating gD from the virus envelope to determine whether a soluble form of gD (sgD) could 
mediate entry of gD-deficient virus. The results showed that sgD enabled entry of gD-deficient 
HSV-1 into CHO-K1 cells bearing the gD receptors HVEM or nectin-1. Using mutant forms of 
sgD that selectively bind to one or the other receptor, we demonstrated that entry by this 
mechanism is receptor specific.  
Investigation of the mechanism of sgD-mediated entry demonstrated that the presence of 
virus at the cell surface was required at the time of sgD-receptor binding, which could be 
explained in part by our observation that sgD rapidly dissociated from the receptor under our 
experimental conditions. In addition, entry was not eliminated instantaneously when receptor-
bound sgD was exposed to 37ºC, suggesting that the active conformation of receptor-bound sgD 
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is not highly unstable. sgD was not stabilized at the cell surface or internalized in the presence of 
gD-deficient virus. Using lysosomotropic agents as well as protease protection assays, we 
obtained no reproducible evidence that sgD-mediated entry takes place by endocytosis. 
Surprisingly, virus attachment to cell-surface GAGs was not required for sgD-mediated 
entry. Furthermore, gD-deficient virus attached to GAG-deficient cells in the absence of sgD, 
revealing a previously unknown binding interaction between the HSV virion and the cell. This 
interaction was shown to be of a less stable nature than the virus-GAG interaction, and may play 
a role in normal virus entry. Our results provide new tools and directions to unravel the still 
incompletely understood events set in motion by gD binding to its receptor. 
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1. INTRODUCTION 
 
1.1. HERPES SIMPLEX VIRUS 
 
1.1.1. Overview 
 
Herpes simplex virus type 1 (HSV-1) is a member of the the Herpesviridae family.  The 
herpesviruses are extremely common and over 100 have been identified in a wide variety of 
animal species, from chickens to turtles to fish.  
The Herpesviridae family is divided into the alpha, beta and gamma subclasses based on 
biological characteristics and genomic analysis.  Nine human herpesviruses have been isolated 
thus far.  Herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and 
varicella zoster virus (VZV) belong to the alphaherpesvirus subfamily. Alphaherpesviruses are 
characterized by having a broad host range, short replication cycle, rapid spread in cell culture 
and the ability to establish latency in sensory neurons (154). Four human herpesviruses 
belonging to the Betaherpesvirus subfamily are cytomegalovirus (CMV), human herpesvirus 6A 
(HHV6A), human herpesvirus 6B (HHV6B) and human herpesvirus 7 (HHV7). Members of this 
subfamily have a host range that is confined to a specific species, a longer replication cycle, 
spread slowly in cell culture, and establish latency in secretory glands and lymphoreticular cells. 
Finally, Epstein Barr virus (EBV) and human herpesvirus 8 (HHV8 or KSHV) are the two 
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 human Gammaherpesviruses, and are characterized by having a host range that is limited to the 
family level and establishing latency in the lymphoid system. 
Disease caused by human herpesviruses include chickenpox and shingles caused by 
VZV, infectious mononucleosis caused by EBV and HCMV, Kaposi’s sarcoma caused by 
KSHV, childhood roseola caused by HHV6A, genital herpes caused by HSV-2, and cold-sores 
caused by HSV-1. 
 
1.1.2. HSV disease 
 
HSV is an important human pathogen,  and is the most extensively studied of the herpesviruses.  
HSV is contacted when mucosal epithelia or abraded skin is exposed to secretions containing 
virus from an infected individual.  During the lytic cycle, the virus actively replicates in the host 
epithelial cells until the cells are destroyed, eliciting an immune response, which contributes to 
the formation of the commonly known cold sores or blisters. The virus then enters the nerve 
endings of the peripheral sensory nerves that innervate the primary site of infection, and travels 
by retrograde transport to the cell bodies of the sensory ganglia, where it enters a latent state, in 
which the viral genome is maintained in episomal form, and all viral gene expression is silenced 
[reviewed in (85)]. This allows the virus to evade immune surveillance and persist for the entire 
lifetime of the host. HSV can be reactivated from its quiescent state by various stimuli, such as 
stress, UV light, or tissue damage. Upon reactivation, the virus travels back to the site of primary 
infection and may cause recurrent lesions on mucosal epithelium, skin, and the cornea. Keratitis 
caused by recurrent corneal HSV infections is the leading cause of blindness in the United States. 
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 Occasionally, complications such as encephalitis and disseminated infection in newborns and 
immunocompromised individuals can occur [reviewed in (59)].   
 
1.1.3. Virion composition 
 
A herpesvirus virion consists of a DNA core, an icosahedral capsid and tegument, surrounded by 
an envelope made up of a lipid bilayer containing various viral proteins and glycoproteins. The 
HSV-1 double-stranded linear DNA genome consists of 152 kbp and encodes at least 84 gene 
products [reviewed in (153)].  It includes unique long (UL) and unique short (US) sequences that 
are flanked by inverted repeats on both ends (RL and RS). The repeats associated with the UL 
region are designated ab and b’a’ and the US region repeats as a’c’ and ca (Figure 1) (66, 165).  
 
 
UL US 
RL RSRS RL
a   b b’  a’  c’ c   a
Figure 1.  Schematic representation of the HSV-1 genome. 
The HSV genome consists of a long (L) and short (S) component. Each of these components 
includes a unique sequence (UL and US) flanked by inverted repeats (RL and RS). The repeat 
sequences of the long component are designated ab and b’a’, and the repeat sequences of the 
short component are a’c’ and ca (66, 165). 
 
Several genes that lie in the repeat regions of the HSV genome exist in two copies (ICP0, 
ICP4 and γ134.5). Because of the presence of the inverted repeats, the HSV genome can readily 
undergo homologous recombination, causing the L and S portions to be inverted in respect to 
each other. Each of the four resulting isomers is found in equimolar amounts in infected cells. 
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 The viral DNA is tighly packed in a disordered form (49, 200) and enclosed in an 
icosahedral capsid composed of 162 capsomers (150 hexons and 12 pentons) (77). The pentons 
are found at the faces and edges of the capsid, and the hexons are located at the vertices. Each 
hexon is comprised of 6 molecules of VP5 (virion protein), the major capsid protein, and six 
molecules of VP26. Eleven of the pentons are composed of a UL19 pentamer. The twelfth penton 
is a fascinating structure called a portal which comprises twelve molecules of UL6 (124). Viral 
DNA is packaged inside the capsid by being threaded through the portal. Three types of capsids 
can be isolated from cells infected with HSV, and are designated A for empty capsid, B for 
capsid filled with the VP22a scaffolding protein, and C for a mature, DNA-containing capsid 
(77). 
Surrounding the capsid is an amorphous material called the tegument that includes 
several important viral proteins, such as VP16, which stimulates the initiation of viral gene 
expression [reviewed in (153)]. The virion is then enclosed by an envelope composed of a lipid 
bilayer, in which the HSV glycoproteins are embedded (Figure 2). 
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tegument 
                                     
capsid 
glycoprotein spikes 
envelope 
DNA 
Figure 2. EM micrograph depicting HSV-1 virion structure. 
The HSV virion is comprised of a double-stranded linear 152 kbp genome enclosed in an 
icosahedral capsid. The capsid is surrounded by an amorphous tegument, and the entire structure 
is enclosed in an envelope, containing the viral glycoproteins. Modified from Milne et al., J. 
Virology, June 2005 (119). 
 
1.1.4. HSV life cycle 
 
Virus enters the host cell by binding and fusion of the viral envelope with the cell surface 
membrane, and release of the viral capsid into the cytoplasm of the cell. A detailed description of 
the entry process will follow in section 1.2.  
Upon entry into the cytoplasm of the cell, the capsid with the intact tegument is  
transported via microtubules to the nuclear membrane (103, 105, 133, 171). During transport, 
some of the tegument proteins dissociate from the capsid and begin to interact with the proteins 
in the cell and modify the cellular environment on the behalf of the virus. After reaching the 
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 outer nuclear membrane, the capsid docks at the nuclear pore, and viral DNA is injected into the 
nucleus (Figure 3) [reviewed in (116)].  
 
 
Figure 3. Virus replication cycle. 
HSV entry into a host cell is initiated by binding of the virus to receptors at the cell surface, 
followed by fusion of the viral envelope with the cell membrane, and release of the viral capsid 
into the cytoplasm of the cell. The naked capsid is then transported via microtubules to the 
nuclear pore, where the viral DNA is injected into the nucleus. Replication of viral DNA and 
capsid assembly occurs in the nucleus, after which the capsid buds into the inner nuclear 
membrane, acquiring its first envelope, fuses with the outer nuclear membrane, and is released 
into the cytoplasm. The naked capsid then buds into trans-Golgi network, where it acquires its 
complement of glycoproteins, and the enveloped virion is transported to the cell membrane and 
released to the outside of the cell. Taken from Mettenleiter, T.C., Virus Research, 2004 (116). 
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 HSV-1 replication occurs through a highly regulated cascade of gene expression 
[reviewed in (153)], and is broken down into three phases: α or immediate early (IE), β or early 
(E), and γ or late (L). All viral genes are transcribed by the cellular RNA polymerase II (1, 32). 
The first viral genes to be transcribed are the α or immediate early (IE) genes. α gene promoters 
contain many binding sites for cellular transcription factors. VP16, which is a viral transactivator 
that is brought into the cell in the viral tegument, plays a role in the expression of α genes  (4, 14, 
142). α gene expression peaks between two to four house post infection (hpi), and includes six 
viral proteins (ICP0, ICP4, ICP22, ICP27, ICP47 and Us1.5), most of which serve as 
transcription factors for the next stages of viral gene expression [reviewed in (153)]. ICP4 is a 
transcriptional regulator that is required for the expression of all viral proteins after the α phase 
(22, 37, 89, 143, 187). ICP0 is a nonspecific transactivator, and is not required for infection, but 
increases the production of virus from infected cells by 10- to 100-fold (160, 177). 
 β gene expression is induced by the production of α gene products, and peaks 4-8 hpi 
[reviewed in (153)]. β gene products include proteins that are involved in viral DNA replication 
and the production of nucleotides so that viral DNA synthesis can proceed in non-dividing cells. 
Several β proteins are viral DNA polymerase (UL30), ssDNA binding protein (UL29), 
ribonucleotide reductase (UL39 and UL40), which reduces ribonucleotides to 
deoxyribonucleotides, thymidine kinase (UL23), which phosphorylates nucleosides to provide 
nucleoside triphospate precursors for DNA synthesis. 
 The final stage of viral gene expression is broken down into two phases: γ1 and γ2. γ1 
genes are know as the early-late genes [reviewed in (153)]. Their expression peaks relatively 
early in infection (8-12 hpi), and is stimulated several-fold by the synthesis of viral DNA. γ2 
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 gene expression requires viral DNA synthesis and peaks later on in infection (12-16 hpi). Late 
genes include HSV glycoproteins and capsid proteins. 
 Upon arrival in the nucleus, the HSV genome localizes in punctate structures called 
prereplicative sites near cellular ND10 structures (112). As synthesis of viral DNA progresses, 
the newly made HSV genomes are concentrated in globular complexes called replication 
compartments (80, 183).  
 Seven viral proteins are required for the replication of the HSV DNA (18, 194): viral 
DNA polymerase (UL30) (144), ssDNA-binding protein (UL30 or ICP8) (28), processivity factor 
(UL42), origin-binding protein (UL9) (38), and the helicase-primase complex comprising UL8, 
UL8 and UL52 (34, 153). Three origins of replication are present in the HSV-1 genome, although 
only one is required for successful replication of the virus in cell culture (44, 100, 120, 184, 189). 
oriS lies in the repeat region of the S portion of the viral genome, and therefore exists in two 
copies. oriL lies in the long region of the viral DNA.  
 Previously it was believed that the incoming genome circularizes upon entry into the 
nucleus, and that this form serves as the template for HSV DNA replication (54, 141, 151). 
Recently, Jackson and DeLuca presented evidence that the template for HSV DNA replication 
during the lytic cycle is actually linear and that ICP0 controls the genome configuration upon 
infection (81). It was also previously believed that viral DNA is synthesized by a rolling-circle 
mechanism, resulting in “head-to-tail” concatemers (82). In their report, Jackson and DeLuca, 
suggest that instead viral DNA replication may proceed from the three origins of replication 
resulting in complex DNA structures which are then modified by viral proteins and homologous 
recombination. 
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  Viral DNA is packaged in pre-assembled capsids in the nucleus [reviewed in (77)]. 
Capsid proteins are translocated to the nucleus after being synthesized in the cytoplasm, where 
they are assembled with the assistance of the scaffolding proteins VP22a. Concatemeric viral 
DNA is cleaved into single unit genomes and threaded through the portal of the capsid. 
 The mature capsid then embarks on its journey to reach the outside of the cell, where it 
will be released, and become able to infect another cell. It begins by budding into the inner 
nuclear membrane, where it acquires its primary envelope [reviewed in (116)]. It then fuses with 
the outer nuclear membrane, and is released into the cytoplasm of the cell. Next, the naked 
capsid buds into the trans-Golgi network, where it obtains its secondary envelope, along with 
most of the tegument proteins and glycoproteins. Interactions have been identified between the 
tegument and the glycoproteins (45, 61, 201) and between the tegument and the capsid (114, 
200). According to one model, the tegument proteins serve as a bridge between the capsid and 
the membrane-bound glycoproteins, directing capsids to the sites of envelopment, and then 
allowing virions to bud into cellular organelles (87). From the trans-Golgi network, the 
enveloped virion is transported in a vesicle to the cell membrane. Upon arrival, the vesicle 
carrying the mature virion fuses with the cell membrane, and releases the virus particle to the 
outside of the cell. 
 
1.1.5. The fate of the infected cell 
 
Upon infection, the virus has multiple mechanisms to modify the cell environment in favor of 
viral replication and immune evasion [reviewed in (153)]. After entering the cell, HSV rapidly 
shuts off the host RNA, DNA and protein synthesis (155). The virus has two goals in doing this: 
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 the first is to hijack the cell’s protein and DNA production machinery for itself, and the second is 
to down-regulate cellular proteins which may interfere with its replication or allow its detection 
by the host’s immune system. One viral protein that is involved in this effort is the virion host 
shutoff protein (vhs or UL41) [reviewed in (169)], which is a tegument protein that starts to work 
immediately after the release of the viral capsid into the cytoplasm of the cell. vhs destabilizes 
cellular mRNA, and is thought to either be an RNase itself or cooperate with a cellular RNase in 
some manner. ICP27 is another viral protein that interferes with transcription by repressing 
splicing (139, 161). Other ways by which HSV affects cell function are: 1) degrades or redirects 
cellular proteins to perform functions to support virus replication; 2) blocks cell cycle in G1 or 
G2; 3) blocks apoptosis; 4) blocks antigen presentation by MHC class I; and 5) blocks the cell’s 
dsRNA sensing mechanism [reviewed in (153)].  
 
1.2. HSV-1 ENTRY 
 
1.2.1. Overview 
 
Enveloped virus entry into host cells consists of two stages: binding of the virus to the cell 
surface and fusion of the virus envelope with a cell membrane. Thus, two types of receptors exist 
that interact with virus glycoproteins. A binding receptor is one that simply allows for the 
binding of the virus particle to the cell surface. An entry receptor triggers a conformational 
change in a viral glycoprotein that leads to fusion. In some instances, both functions may be 
served by the same receptor.  
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 A problem that each virus family has evolved to solve is how to trigger its fusion 
mechanism only after coming in contact with the host cell, since indiscriminate fusion would 
cause virus particles to fuse together before reaching their target cell. All enveloped viruses bear 
glycoproteins in their envelopes, one of which contains a fusogenic peptide that is inserted into a 
membrane of the host cell to initiate the fusion process between the viral envelope and a cell 
membrane. Most viruses express only one or two glycoproteins in their envelopes, making the 
identification of the fusogen-bearing glycoprotein fairly simple. HSV is a large and extremely 
complicated virus, containing 11 glycoproteins in its envelope, four of which are essential for 
entry [reviewed in (13)]. This multitude of glycoproteins greatly complicates the elucidation of 
the fusion and entry process. The fusogen-bearing glycoprotein normally exists in a meta-stable 
state, and is easily triggered to undergo a conformational change, exposing the fusion peptide, 
after encountering the appropriate trigger.  
Enveloped viruses employ two possible routes of entry into a cell: endocytosis or fusion 
at the cell membrane. Viruses that take the endocytic pathway fuse with the endosomal 
membrane to enter the cell cytoplasm upon exposure to an acidic environment, while viruses that 
fuse at the cell membrane depend on a glycoprotein-receptor binding event to initiate fusion. In 
addition, a hybrid system of entry is utilized by several viruses which enter through a pH 
independent, caveolae-mediated endocytosis pathway (90, 109, 117, 131, 149, 150, 157, 176). A 
possible explanation for why a virus would need to take this pathway would be to gain access to 
a fusion-triggering co-receptor that is present only in a caveosome. Recent evidence has also 
been presented that several viruses are able to utilize multiple entry pathways, when the main 
pathway of entry is blocked (Sieczkarski 2002 – influenza, Damm & Helenius SV40?). 
 11
 HSV entry is initiated by binding of viral glycoproteins B (gB) and C (gC) to heparan 
sulfate (HS) glycosaminoglycan (GAG) side chains of cell-surface proteoglycans (104, 166, 175, 
195). This step is thought to concentrate virus at the cell surface and allow glycoprotein D (gD) 
to engage the entry receptor, such as HVEM (HveA), nectin-1 (HveC), or 3-O-sulfated heparan 
sulfate [reviewed in (13, 172, 173)]. Receptor binding by gD is believed to set in motion the 
fusion process, which requires gB and the gH:gL heterodimer for completion. Although it has 
been shown that four glycoproteins (gB, gD, gH and gL) are required for HSV entry, the 
individual roles of these glycoproteins are still largely unknown. 
 
1.2.2. Fusion mechanisms employed by other enveloped viruses 
 
Fusion of two biological membranes is a process that requires an investment of energy. In the 
case of fusion of an enveloped virus with a cell-membrane, the energy is derived from a large 
conformational change that is carried out by a viral glycoprotein [reviewed in (27)]. The 
conformational change is triggered either by a low pH environment in an endocytic compartment 
or by the binding of the glycoprotein to a cell-surface receptor, and leads to the insertion of a 
hydrophobic fusion peptide into the opposing cellular membrane. This event is thought to de-
stabilize the membrane, and allow for the fusion process to proceed. The details of the ensuing 
fusion process are still largely unknown. 
 Two types of viral fusion proteins have been identified thus far. Type I fusion proteins 
form spiky projections that are positioned perpendicular to the viral envelope [reviewed in (27)]. 
Each protein is synthesized as a single-chain molecule, which then assemble into trimers. Each 
protein is cleaved by host proteases, which allows it to enter a metastable state and then carry out 
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 the fusion process. The newly created amino terminus contains the fusion peptide, and a region 
near the C-terminus contains heptad repeats that form coiled-coil structures that aid in the fusion 
process. After encountering the appropriate trigger, the fusion peptide is inserted into the 
opposing membrane. The protein is then refolded into a trimeric coiled-coil, thereby drawing the 
two membranes into close proximity to initiate fusion (Figure 4). The influenza HA glycoprotein 
is the best characterized fusion protein in this class. 
 Type II fusion proteins lie parallel to the surface of the viral envelope, and are found in 
members of the Flaviviridae family [reviewed in (67)]. They are synthesized in a metastable 
form as heterodimers with another viral glycoprotein. Upon entry, the partner glycoprotein 
dissociates after being exposed to a low pH of an endosome. The fusion protein in turn 
undergoes a large conformational change, and enters a homotrimer conformation. The internal 
fusion peptide is propelled towards the endosomal membrane, initiating fusion of the two 
membranes.  
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Figure 4.  Fusion of envelope viruses with a Type I fusion protein. 
a) A type I viral fusion protein binds to its receptor at the cell-surface, triggering a 
conformational change in the viral fusion protein (b-d). c) Fusion peptide is inserted into the 
target cell membrane. d) Formation of the trimeric coiled-coil draws the viral and cell 
membranes into close proximity. Modified from Colman, P.M. and Lawrence, M.C., Nature 
Reviews, April 2003 (27). 
 
 
1.2.3. HSV entry pathway 
 
Until recently, HSV was believed to enter all cells by fusion at the cell surface. However, several 
studies that have been published in the last few years showed that HSV entry into certain cell 
types can occur by endocytosis. Nicola et al. demonstrated that HSV entry into CHO and HeLa 
cells, but not Vero cells, can be inhibited by energy depletion or hypertonic medium, which 
inhibits endocytosis, and by lysosomotropic agents that block the acidification of endocytic 
vesicles (128).  
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 Lysosomotropic drugs have traditionally been used to show whether a virus enters cells 
through endocytosis. They prevent endosome acidification, thereby blocking the necessary 
trigger that the virus requires in order to fuse with the endocytic compartment. Most of these 
drugs also affect the cells in various non-specific ways. Bafilomycin A1 is the most specific 
lysosomotropic agent available today. This drug is thought to specifically inhibit vacuolar H+ -
ATPases that are responsible for lowering the pH of endocytic vesicles (137). Nevertheless this 
drug is fairly new, and it is possible that future studies will show that it as well has other non-
specific effects on the cell. 
Specific methods to elucidate the entry pathway of a virus take advantage of dominant-
negative mutants of components of the endocytosis machinery, such as Eps15, which is an 
essential component of clathrin coated pits (170), or dynamin, which is involved in the formation 
of both clathrin and caveolar vesicles (35, 129). Nevertheless, by blocking endocytosis, these 
methods interfere with many essential cellular processes, and can therefore indirectly affect 
infection. The most reliable method used today to demonstrate endocytosis or lack thereof is 
real-time video microscopy, which allows the tracking of a fluorescently-labelled virus particle 
through endocytic compartments (170).  
In another study, Nicola et al. showed that endocytosis in CHO cells is receptor-
independent, but that expression of a gD-receptor is required for productive infection (125). 
While other viruses require either receptor binding or exposure to low pH to trigger their fusion 
mechanism, these studies suggest that HSV requires both in certain cell types. The reason for this 
unusual requirement is still unknown. A more recent study showed that HSV infection of C10 
murine melanoma cells takes place by yet another pathway: gD-receptor-dependent, but pH-
independent, endocytosis  (119). Whether or not HSV entry by these novel pathways leads to 
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 productive infection is yet to be conclusively proven, as the current studies all relied on the use 
of chemical agents to block endocytosis. As previously mentioned, chemical agents can have 
secondary effects on the cells that interfere with infection. 
 
1.2.4. HSV attachment 
 
Heparan sulfate (HS) is an HSV binding receptor. Elimination of the HSV-HS interaction 
decreases virus infectivity, but does not abolish it altogether, indicating that fusion can still occur 
in its absence (62). Several lines of evidence demonstrate the binding role of HS in HSV entry. 
CHO cell mutants that are defective in GAG synthesis are highly resistant to HSV infection and 
binding of virus to these cells is greatly impaired (3, 166).  Mutant viruses that are gC-deficient 
infect cells with a 10- to 20-fold reduced efficiency (71). 65% less gC-deficient virus particles 
bound to Vero cells as compared to wild type virus while the deletion of the HS binding domain 
of gB reduced the amount of bound virions by only 20% (96).  The effect of deleting both gC 
and the HS binding domain of gB reduced the number of bound viruses by 80% as compared to 
wild type virus (96). The gD-receptor interaction is thought to bind the other 20% of virus in the 
absence of the gB and gC binding functions (3). The affinity of the  gC-HS interaction is 30-fold 
higher than that of the gD-receptor interaction (158), which together with the greater abundance 
of HS on the surface of cells, may explain the greater role of HS in HSV binding. 
Although the interaction of gB with HS appears to be unnecessary and redundant, it may 
be required for virus binding to certain cell types or have an additional role in entry that does not 
involve binding. For example, it was shown that a gC-negative virus was only able to infect 
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 MDCK cells from the basolateral surface (163). In addition, gC and gB appear to bind to 
different HS structures and with different affinities (68, 181).  
 
1.2.5. HSV fusion 
 
Initial binding of the HSV virion to HS allows for the efficient interaction of gD with the entry 
receptor on the cell surface. Three structurally unrelated gD entry receptors have been identified 
thus far, HVEM (HveA) (121), nectin-1 (HveC) (55), and 3-O-sulfated heparan sulfate (167), 
and it has been demonstrated that the gD-receptor interaction is absolutely required for HSV 
entry (83, 84). Penetration of virus also requires the action of gB, gH, and gL. Deletion of any 
one of these genes results in the production of virus that is able to bind to cells but can not 
penetrate (10, 43, 98, 156).  Neutralizing antibodies that target each of the four essential 
glycoproteins have been isolated, supporting the requirement for each in the entry process (60, 
123, 130, 134, 136). In addition, several groups have shown that these four glycoproteins are 
necessary and sufficient to induce cell-cell fusion when they are expressed in the same 
membrane (138, 182), confirming that they constitute the minimal HSV fusion machinery. 
Nevertheless, it has not yet been determined how gD initiates the fusion cascade upon receptor 
binding, or what the individual roles of the other three essential glycoproteins are in the entry 
process. 
 According to the current model for HSV entry, binding of gD to its receptor triggers a 
conformational change in gD, which allows it to send a fusion signal to the other three essential 
glycoproteins (Figure 5) (174). An alternative hypothesis is that the gD-receptor interaction 
simply serves to tightly bind the viral envelope and the cell membrane, allowing for another 
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 event to trigger fusion, such as the binding of another glycoprotein to a co-receptor. In either 
case, the actual fusion process is thought to be mediated by one or all of the other essential 
glycoproteins.  
 
 
a 
b c d
Figure 5. Model for HSV entry.  
gD binds a specifice cell-surface receptor (a), undergoes a conformational change (b), and is then 
able to transmit the fusion signal to the other essential glycoproteins (c). Fusion process is 
carried out by one or more of the other essential glycoproteins (d). 
 
 
gD itself is not likely to be the fusogen for several reasons. First, a viral fusogen must be 
anchored in the viral envelope in order to enable fusion of the two opposing membranes, and it 
has been demonstrated that membrane-anchorage of gD is not essential for its function. gD can 
function in cell fusion when its ectodomain is linked to a GPI anchor (86) and a soluble form of 
the gD ectodomain can mediate entry of a gD-deficient virus, as reported earlier by Cocchi et al 
(23), and us in the current study. Second, glycoprotein D is missing from the envelopes of β and 
γ herpesviruses, as well as VZV, and is therefore thought to be the initiator of fusion in HSV and 
not an integral part of the conserved fusion machinery.  
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 An important study that was instrumental in establishing the cascade model of HSV entry 
was conducted by Fuller and Lee (46). These authors showed that virions that were attached to 
the cell-surface, in which gD or gH were neutralized by antibodies, had a distinctly different 
morphology than wild type virus. gD-inactivated virions were loosely associated with the cell 
surface in contrast to wild type virions, which were associated more tightly. Virions with 
inactivated gH appeared to be arrested at a later stage of fusion, and formed fusion bridges with 
the cell, suggesting that gH was involved in a fusion step that was further downstream than gD.  
 After the gD receptors were identified and it was conclusively shown that the gD-
receptor interaction is absolutely required for HSV entry, the main questions facing the HSV 
entry field were: 
1. Does the gD-receptor interaction serve to tightly bind the virus to the cell or does it enable gD 
to send a fusion signal to the other viral glycoproteins? 
2. Does the fusion signal go through the viral envelope or cell membrane? 
3. Which viral glycoprotein(s) does gD interact with to communicate the fusion signal? 
4. How do gB and gH participate in the fusion process? 
5. Which glycoprotein(s) is the fusogen? 
In the last few years several studies have begun to address all of these issues. The 
strongest evidence against the hypothesis that states that the purpose of the gD-receptor 
interaction is only to tightly bind virus to the cell was provided by studies showing that both the 
gD receptors and gD itself can function to mediate entry in soluble form. Qing Bai and 
Heechung Kwon in our laboratory demonstrated that soluble nectin-1 and soluble HVEM can 
mediate entry of HSV containing a full complement of viral glycoproteins into gD-receptor 
deficient CHO-K1 cells (94). This study also provides strong evidence to show that the fusion 
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 signal is transmitted through the viral envelope and not through the cell membrane. The current 
study and published work by others demonstrate that soluble gD can mediate entry of gD-
deficient HSV particles into receptor-bearing cells. Since membrane anchorage of both gD or the 
gD receptor is thus not required for HSV entry, it can be concluded that the purpose of the gD-
receptor interaction is to trigger fusion and not to tightly bind virus to the cell. 
How gD is able to initiate fusion is currently the most important question facing the HSV 
entry field, and is under intense investigation by several laboratories. The HVEM binding 
domain on gD has been clearly defined (17, 30, 196, 197), and evidence for the localization of 
the nectin-1 binding domain has recently been presented (detailed below) (29, 106). In addition, 
a gD domain that is involved in entry, but not binding to either receptor was recently identified 
by two laboratories (detailed below) (23, 50, 198), providing further support that gD does have a 
non-binding role in entry. Nevertheless, a binding partner in the HSV envelope for gD has thus 
far not been identified. 
Whitbeck and co-workers provided the first evidence of a link between gD-receptor 
binding and a downstream effect on one of the other essential glycoproteins (C. Whitbeck, Y 
Zou, R. Milne, G.H. Cohen and R.J. Eisenberg. 29th International Herpesvirus Workshop, abstr. 
2.13, 2004). These authors showed that the proteinase digestion pattern of gB in the virion 
changed upon gD association with soluble nectin-1.  
Some evidence exists for complex formation between gD and the other essential 
glycoproteins.  First, Handler et al. demonstrated an association between gD and glycoproteins B 
and H by cross-linking of purified HSV, immuno-precipitation of one glycoprotein, and probing 
Western blots of the precipitate with antibodies against other glycoproteins (64).  The results 
from this study demonstrated the existence of oligomers containing glycoproteins D, B and C. 
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 Another cross-linking study conducted by Rodger et al. supported the findings of this report for 
wild type virus (152). However, when this group examined virus particles that lacked either 
glycoprotein B, C or D, they found that the cross-linking interactions between the remaining two 
glycoproteins remained unaltered.  
In the last year, studies addressing the existence of an HSV fusogen have been published. 
Gianni et al. reported the presence of a potential fusion peptide and heptad repeat sequences in 
gH, suggesting that this molecule may be the fusogen (52, 57, 58). In addition, Galdiero et al. 
identified several sequences in gH that can induce fusion of large unilamellar vesicles (52, 57, 
58).  
 
1.2.6. HSV binding and entry receptors 
1.2.6.1. Heparan sulphate 
 
Heparan sulphate (HS) is thought to be expressed in all non-circulating tissues. It consists 
of long chains of repeating modified disaccharide units, with alternating N-sulfate or N-acetyl 
glucosamine (GlcN) residues and glucuronic acid (GlcA) or iduronic acid (IdoA) residues 
[reviewed in (88)]. Although the majority of the HSV-1 HS binding can be accounted for by 
electrostatic forces mediated by basic residues of gB and gC and negatively charged sulfate and 
carboxyl groups of the HS chains, there is a significant amount of specific interactions that exist 
between these molecules. In addition, not all cells that express HS necessarily contain binding 
sites for gB and gC.  Binding of gB and gC to HS on the cell surface is dependent on a preferred 
arrangement of the disaccharide sugar residues on HS (42) and specific amino acid sequences on 
gB and gC (96, 108, 180). The HS binding domain of gB has been mapped to a lysine-rich (pK) 
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 sequence consisting of residues 68 to 76, while three different domains of gC mediate its binding 
to HS (96, 168). Glycoproteins B and C appear to bind to different domains of HS, since gC but 
not gB binding to HS can be inhibited with several different compounds (68, 69). In addition, 
gB’s interaction with HS seems to be more specific, since higher concentrations of sodium 
chloride were needed to disengage the gB-HS complex than gC-HS (181). 
 
1.2.6.2. HSV entry receptors 
 
Three classes of structurally unrelated HSV receptors have been identified through 
expression cloning (13, 25, 167).  The first HSV receptor to be isolated was HVEM (Herpes 
Virus Entry Mediator, also referred to as HveA), belonging to the TNFα/NGF receptor family 
(121).  Next, two HSV receptors belonging to the immunoglobulin superfamily were identified, 
and named nectin-1 (or HveC) and nectin-2 (or HveB) (55, 186). The last HSV-1 receptor to be 
discovered is a 3-O-sulfated derivative of heparin sulfate, but not much information is available 
about its biological role (167).  
HVEM mediates entry of most strains of HSV-1 and 2 and is found on activated 
lymphocytes, epithelial cells, and fibroblasts, but not on neurons (172). HVEM is the principal 
HSV receptor on activated lymphocytes, but not in other cell types, in which the principal 
receptor is nectin-1. In activated lymphocytes, the cellular function of HVEM is to bind the 
ligands LIGHT and lymphotoxin-α (113).  Studies of the physiological role of HVEM have 
shown that the binding of LIGHT can provide a secondary signal for T cell activation [reviewed 
in (33)]. In vivo studies have demonstrated that the LIGHT-HVEM interaction contributes to a 
CTL-mediated immune response (172). The implications of the physiological role of HVEM to 
HSV biology are yet to be established. 
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  Nectin-1 serves as an entry receptor for HSV-1 and 2, pseudorabies virus, and bovine 
herpesvirus type 1. Nectin-1 is broadly expressed on human cell lines, organs, and tissues, such 
as epithelial cells, fibroblasts, and neurons. Three other nectins have been identified thus far 
[reviewed in (179)]. Nectins function as Ca2+-independent homo- and heterophilic adhesion 
molecules, and interact with afadin, which connects them to the actin cytoskeleton. They can co-
localize with cadherins to adherens junctions, as well as function in cell adhesion independently. 
Nectins consist of an amino-terminal V-domain, two C2-like domains, a transmembrane domain 
and a cytoplasmic tail.   
Nectins form homo-cis-dimers, and this formation is essential for the formation of trans-
dimers. Each nectin family member forms homo-trans-dimers, and nectins 3 and 4 also form 
hetero-trans-dimers with nectin-1 that are of a significantly higher affinity than the homo-trans-
dimers (40, 148). The nectin-3 and 4 binding domain of nectin-1 overlaps with its gD binding 
domain (40). 
The nectin-1 V-domain is necessary and sufficient to mediate HSV entry. A truncated 
form of the V-domain fused to the transmembrane region was shown to function in mediating 
entry, indicating that the C2-like domains are not essential (24). In addition, a soluble form of the 
V-domain was shown to mediate HSV entry into receptor-deficient cells (94). 
 Nectin-2, another member of the immunoglobulin family of receptors, mediates the entry 
of several HSV-1 mutants – rid1, rid2 and ANG, but does not allow entry of wild type virus 
(102, 186).  In addition, nectin-2 mediates the entry of HSV-2 and pseudorabies virus (186).  
 
 
 
 23
  
1.2.7. Essential virus components for entry 
1.2.7.1. Glycoprotein D 
 
Glycoprotein D (gD) is a major player in the HSV entry process, and is thought to trigger 
the fusion cascade by binding to a cell-surface receptor.  gD is expressed by all 
alphaherpesviruses, with the exception of VZV, and is thought to be the envelope component 
that confers host and tissue specificity [reviewed by (172)].  
gD is a  type I integral membrane glycoprotein and consists of 369 residues with an 
ectodomain of 316 amino acids, three N-linked oligosaccharide attachment sites (188), and 6 
cysteines that form three disulfide bonds (101). The crystal structure of the gD ectodomain (the 
first 259 residues), unbound and bound to the HVEM receptor has been reported (Figure 6) (16).  
Based on these data and numerous genetic analyses, important conclusions can be drawn about 
the structure of this key molecule.  gD259 consists of a central V-like immunoglobulin fold, with 
large extensions at the N- and C-termini.  The N-terminal residues, which constitute the HVEM 
binding site form a hairpin upon HVEM binding.  In the  crystal structure of free gD, the N-
terminus does not form the hairpin structure. Adjacent to the N-terminal hairpin is an α-helix, 
comprised of residues 224-240.  Residues in the α-helix stabilize the binding of HVEM to the 
hairpin domain, and are also involved in nectin-1 binding and entry.   
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Figure 6.  Crystal structure of gD bound to HVEM. 
Ribbon diagram of the crystal structure of glycoprotein D bound to the HveA receptor.  gD is 
colored in red and green, and HveA in grey.  The α-helix and hairpin structures are indicated.  
(Image created with RasMol). 
 
Using a genetic approach, Chiang et al. defined four functional domains of gD (20). gD 
mutants were constructed by linker-insertion mutagenesis and tested for their ability to 
complement the entry function of a gD-minus virus.  The mutations that failed to complement 
entry were grouped into four functional regions.  Region I corresponds to the hairpin domain, 
region II is part of the Ig-like core, region III includes the α-helix, and region IV comprises the 
un-crystallized portion of gD between the α-helix and the transmembrane domain (Figure 7).  
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Figure 7. Crystal structure of gD in complex with HVEM depicting the functional regions 
of gD. 
Crystal structure of gD depicting three of the four functional regions of gD defined by linker-
insertion mutagenesis study conducted by Chiang et al. (20). (Image created with RasMol). 
 
Mutational analyses have revealed distinct but overlapping regions of gD that contribute 
to binding of the different cognate receptors. Numerous mutants have been described that are 
competent for binding and entry via nectin-1, but not HVEM (17, 30, 31, 93, 102, 118, 121, 186, 
191, 196, 197). Moreover, rare mutants with the reciprocal profile have now been identified as 
well (29, 106) (Q. Bai, W. Ali Shah, J.B. Cohen, R.J. Eisenberg, G.H. Cohen and J.C. Glorioso. 
Abstr. 26th International Herpesvirus Workshop, abstr. 2.10, 2001). These studies have helped to 
define the HVEM binding site, localized mainly to the N-terminal hairpin domain of gD, in 
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 agreement with the crystal structure. They are beginning to bring the nectin-1 binding domain, 
which includes several discontinuous epitopes near the top of the α-helix, into sharper focus.  
Identification of a gD domain that is involved in entry, but not receptor binding, has been 
a core objective in the HSV entry field for the past decade. It has been demonstrated that several 
monoclonal antibodies do not interfere with virus binding to HVEM, but neutralize virus entry 
into cells expressing this receptor (93, 127).  In addition, several mutations in gD abrogated the 
ability of virus to enter cells, while preserving the ability of gD to bind both receptors. These 
studies identified regions important for entry consisting of residues 216-221, 243, 272-279, and 
277-299. Recently, Cocchi et al. further defined an entry domain between residues 260 and 310 
by showing that a soluble form of gD created by truncation of the ectodomain after position 285 
(gD285),  but not gD260, was able to mediate entry of a gD-deficient virus, although both 
molecules were capable of binding to nectin-1 and HVEM (23). These authors named this region 
the pro-fusion domain (PFD), and suggested that this domain is directly involved in interactions 
between gD and another viral glycoprotein.  Zago et al. supported this finding by showing that a 
chimeric  HSV/PrV gD can substitute for HSV gD in entry and cell-cell fusion only if the first 
285 amino acids of the chimeric molecule are derived from the HSV gD (198). Since the first 
261 amino acids of HSV gD were sufficient for binding to both the HVEM and the nectin-1 
receptors, these results showed that a domain between residues 262 and 285 was required for 
entry but not receptor binding.  Based on the observation that 5- and 10- amino acid deletions 
across this region did not identify a sub-domain that is critical for cell-cell fusion, these authors 
proposed that this domain is not directly involved in the still hypothetical interaction of gD with 
another HSV glycoprotein, but instead may constitute a flexible stalk that is involved in 
promoting a conformational change in gD or the proper positioning it of gD to trigger fusion. 
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 When the crystal structure of gD was solved, it was puzzling that no major 
conformational change could be detected between the receptor-bound and free forms of gD. It 
was hypothesized that the remainder of the gD ecto-domain outside of the crystallized portion 
(residue 260-310) might be involved in a larger conformational change than what the crystal 
structure revealed. Recently, Fusco et al. demonstrated that this is indeed the case by showing 
that a soluble form of this region (named the PFD from a previous study) bound soluble gD 
truncated at amino acid 260 (gD260) (50). This interaction was disrupted by binding of gD260 to 
either the HVEM or nectin-1. These authors proposed a model in which gD exists in a closed 
conformation before receptor binding, in which the C-terminal PFD interacts with the N-
terminus, and that after receptor binding, gD enters an open conformation in which it is able to 
transmit the fusion signal to other glycoproteins.  
The cytoplasmic and transmembrane domains of gD are dispensable for gD’s entry 
function (41, 192).  The cytoplasmic tail of gD was deleted from residue 343 and replaced with 
the cytoplasmic domain of CD8 with no effect on the infectivity of gD-deficient viruses 
complemented with this chimeric molecule. The transmembrane domain of a Golgi-resident 
enzyme was also substituted for that of gD.  The resulting recombinant virus replicated to wild 
type levels.  
 
1.2.7.2. Glycoprotein B 
 
Glycoprotein B is another essential player in fusion and entry of HSV.  It is the most 
highly conserved glycoprotein in the Herpesviridae family (135) and is the prime candidate to be 
the fusogen.  gB consists of 904 amino acids, comprising an ectodomain of 696 amino acids, a 
cytoplasmic tail of 109 residues, and a 69 amino acid C-terminal hydrophobic stretch that is the 
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 predicted membrane-anchoring domain (9).  The C-terminal hydrophobic stretch is predicted to 
contain three 20-21 amino acid segments, which span the membrane three times (132).  Various 
sequences in the ecto-, transmembrane, and cytoplasmic domains of gB are required for the 
fusion and entry functions of the virus (10, 11, 51, 72, 73, 110, 146, 185). Regions in the external 
and cytoplasmic domains of gB have been identified which alter the rate of entry of HSV-1 (9, 
36, 51, 73).  Wild-type HSV does not cause significant cell-cell fusion upon infection, whereas 
mutants that cause extensive polykaryocyte formation (syn mutants) have been readily isolated 
(147).  Syn mutations have been mapped to the cytoplasmic domain of gB (9-11, 51).  Taken 
together, these data strongly suggest that HSV fusion involves communication between the ecto- 
and cytoplasmic domains of gB through the predicted transmembrane region. 
Glycoprotein B can be extracted from virions or cells in the form of homodimers (21, 63, 
74, 162).  Dimerization domains of different affinities have been mapped (74, 145), and the 
position of the strongest oligomerization site was narrowed down to residues 626-653 (97).  
1.2.7.3. Glycoprotein H 
 
Glycoprotein H is the third and final participant that is essential for the entry function of 
HSV.  It forms a heterodimer with gL, which is a small, non-membrane-anchored glycoprotein 
(79).  Complex formation with gL is required for the proper processing of gH, as well as for 
infectivity of the virus (79).  gH consists of 838 amino acids, with an ectodomain of 786 
residues, a cytoplasmic tail that is 14 residues long, and a transmembrane domain of 21 amino 
acids.  As with gB, all three domains of gH play a crucial role in the entry process of the virus as 
mutations in each of the three domains have been shown to abolish infectivity (8, 52, 65, 193).  
Syn mutations map to the gL glycoprotein of the gH:L complex (99).  
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 Recently, several fusogenic domains have been identified in gH, suggesting that this 
glycoprotein may participate in mediating the actual fusion process. Gianni et al. used the 
bioinformatics tool ENSEMBLE to identify two membrane α–helices in gH, located at positions 
377-397 and 513-531 (57). Deletion of each of these domains from gH eliminated its ability to 
function in cell-cell fusion and to complement entry of a gH- virus. In addition, substitution of 
these domains with the fusion peptides of HIV gp41 and VSV-G partially rescued the cell-cell 
fusion activity and infectivity of gH. In a second report from this group, a potential heptad repeat 
(HR) with a high probability to form a coiled coil was identified at position 443-471 by using an 
optimized Lupas algorithm (58). A double mutation in the HR region predicted to eliminate the 
ability of this sequence to form a coiled coil abolished the ability of gH to complement entry of a 
gH- virus. A peptide corresponding to this sequence was also shown to inhibit HSV entry. In 
another report by Galdiero et al., the hydrophobicity-at-interface scale proposed by Wimley and 
White was used to identify six hydrophobic sequences in gH that have the potential to interact 
with target membranes (53). Four peptides corresponding to these sequences were able to induce 
fusion of large unilamellar vesicles, and experiments with mixtures of different peptides showed 
that these regions may act in a synergistic manner. One of the peptides identified by this group 
(residues 381-420) represents a region that somewhat corresponds with one of the domains 
identified by Gianni et al. (377-397). The effect of mutations in the regions identified by the 
Galdiero group on HSV infectivity or cell-cell fusion still need to be determined in order to 
establish the role of these domains in virus fusion. 
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2. SPECIFIC AIMS 
 
According to the currently favored model for HSV entry, gD binding to a cognate receptor 
induces a conformational change in gD which signals activation of the fusion machinery by 
enabling communication with the likely effector components of the fusion apparatus, gB and/or 
gH:gL [reviewed in (174)]. Identifying the exact sequence of events in the complex fusion 
cascade has been hampered by the inability to isolate the role of individual glycoproteins in the 
process.  
 In order to overcome this problem, we took the approach of separating gD from the viral 
envelope and tested its ability to mediate entry in soluble form. We reasoned that if gD would 
have the ability to mediate entry when separated from the viral envelope, this system could be 
used to further dissect the early events in the HSV entry process.  
 
Aim 1: Determine whether gD can function to mediate HSV-1 entry in soluble form. 
The goal of this aim was to determine whether a soluble version of the gD ectodomain, referred 
to as soluble (s) gD, could complement a gD-deficient virus for entry and to compare aspects of 
this system with entry directed by envelope-anchored gD. The results showed that soluble gD 
can mediate entry of gD-deficient HSV-1 into CHO cells in a manner dependent on the presence 
of a cell-surface receptor for gD. In order to estimate the efficiency of sgD-mediated entry, 
TaqMan PCR was utilized to compare the virus particle concentrations in our stocks of gD-
deficient and gD-complemented virus used in entry assays. Receptor specificity of sgD-mediated 
entry was demonstrated by producing sgD proteins that contained mutations previously shown to 
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 redirect virus entry through either HVEM or nectin-1 when present in the envelope-anchored 
form of gD. The mutant sgDs demonstrated the same receptor-specificity profile as their 
envelope-anchored counterparts. It was concluded that anchorage of gD in the virus envelope is 
not essential for its role in entry. 
 
Aim 2: Characterize the mechanism of sgD-mediated entry 
The goal of this aim was to utilize our system, in which gD separated from the virus particle was 
able to mediate entry, to determine the order of interactions between gD, the gD-receptor and the 
gD-deficient virion containing the other essential glycoproteins. This part of our study was 
initiated by conducting a series of pre-incubations of sgD and the gD-deficient virus with 
receptor-bearing CHO cells. The results showed that while the pre-incubation of virus with the 
cells supported sgD-mediated entry, pre-incubation of sgD with the cells completely eliminated 
entry. Since gD is thought to undergo a conformational change upon receptor binding in order to 
transmit the fusion signal to the other essential glycoproteins, we hypothesized that sgD may fall 
back to an inactive conformation upon receptor binding in the absence of the other virion 
glycoproteins. Upon further investigation, the results showed that although ample amounts of 
sgD were present at the cell surface immediately after pre-incubation, sgD rapidly dissociated 
from its receptor after excess sgD was removed from the media. In addition, the results 
demonstrated that receptor-bound sgD was not inactivated instantaneously upon exposure to the 
permissive temperature of 37ºC, indicating that if sgD does undergo a conformational change 
upon receptor binding, the conformational change is of a stable nature. 
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  As an alternative approach to identify interactions between receptor-bound sgD and the 
virus, the possibility that sgD was stabilized at the cell-surface in the presence of the virus was 
investigated. The results showed no evidence of sgD stabilization. 
 Finally, in light of the recent evidence that virus entry into CHO cells occurs by 
endocytosis, sgD internalizion in the presence of virus was tested. The results provided no 
evidence of sgD internalization in the presence or absence of virus. 
 
Aim 3: Determine GAG-dependence of sgD-mediated entry. 
To determine whether sgD-mediated infection was dependent on virus binding to cell-surface 
GAGs, a cell line (pgsA745-nectin-1) was generated that is GAG-deficient but expresses nectin-
1. The results showed that these cells were susceptible to sgD-mediated entry, demonstrating that 
sgD-mediated entry is not dependent on the presence of GAGs at the cell surface.  
 
Aim 4: Determine the binding mechanism utilized by gD-deficient virus on GAG- cells. 
The occurrence of virus entry into the pgsA745-nectin-1 cells in the absence of GAGs and virion 
gD indicated that viral-cellular attachment took place independent of the known binding events 
between the virus and cellular nectin-1 or GAGs. We reasoned that this could be due to either the 
formation of a sgD-mediated attachment bridge between virion glycoproteins and cell surface 
nectin-1, or to the existence of a previously unknown, GAG- and gD-independent binding event 
between the virus and the cell.  
Binding of gD-deficient virions to GAG-deficient cells was tested in the absence and in the 
presence of sgD by Western blot. The results showed that the gD-deficient virus was capable of 
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 binding to GAG-deficient cells in the absence of sgD, demonstrating the existence of a novel 
binding mechanism.  
 Characterization of the novel binding interaction indicated that i) it is of a less stable 
nature than the virus-GAG interaction, ii) it is also employed by gD+ virus, and iii) virus appears 
to bind better through this interaction in the absence of gD. 
 
Aim 5: Define the pathway of sgD-mediated entry.  
In light of the recent demise of the long-held paradigm that HSV enters all cells by fusion at the 
cell-surface, we wished to investigate the entry pathway of gD-deficient HSV in the presence of 
sgD. To this end, we first attempted to reproduce the results of Nicola et al. demonstrating 
inhibition of virus entry into CHO cells by lysosomotropic agents. Our results yielded 
inconsistent data for HSV, while the same drugs consistently inhibited entry of the control virus, 
VSV, whose entry is well-established to occur by endocytosis. We thus were unable to apply this 
method to investigate the sgD-mediated entry pathway. 
We then attempted to show endocytosis of wild type virus by using a protease protection 
assay, as described by Milne et al. (119). Our results did not show any glycoprotein 
internalization, which would have indicated that endocytosis did occur in our system. 
Finally, we tried to utilize the sgD-mediated entry system to demonstrate the 
internalization of gD-deficient virus in the absence of sgD, based on the observation by Nicola et 
al. that wild-type virus is rapidly internalized into CHO cells in the absence of gD receptors 
(126). This assay showed that if internalization is occurring, it is at a rate that is significantly 
reduced from the reported t1/2=9 min. 
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 In conclusion, we found no evidence of endocytosis of wild type or gD-deficient virus 
into CHO cells. Further studies are required to clarify the discrepancy between these results and 
those of Nicola and co-workers. 
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 3. MATERIALS AND METHODS 
 
3.1. Cells and Viruses 
 
Vero and 293T cells were obtained from the ATCC. VD60, a gD-complementing cell line, was a 
gift from Dr. David C. Johnson (Oregon Health Sciences University) (98). Vero, VD60 and 293T 
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA) 
supplemented with 5% fetal bovine serum (FBS; Gibco). Chinese hamster ovary cells (CHO-
K1), and CHO-K1 cells stably expressing HVEM or nectin-1 were kindly provided by Dr. 
Patricia Spear (Northwestern University), and grown in F-12K medium (Gibco) supplemented 
with 10% FBS. CHO-nectin-1 and CHO-HVEM cells were maintained under selection with 400 
μg/ml G418 (Gibco). pgsA745 cells that are derived from CHO-K1 and are defective in GAG 
synthesis (39) were obtained from the ATCC (CRL-2242). pgsA745-nectin-1 cells were derived 
from the pgsA745 cell line  by transfection with a full-length nectin-1 cDNA expression plasmid 
(178) and selection of hygromycin B resistant clones. pgsA745-nectin-1 cells were maintained 
under hygromycin B selection. J1.1-nectin-1 cells were derived by stably transfecting J1.1-2 
cells (kindly provided by Dr. Gabriella Campadelli-Fiume) with the nectin-1 plasmid described 
above (178), and selecting hygromycin B resistant clones. 
K∆Us3-8Z is derived from HSV-1 KOS. This virus contains a lacZ reporter gene under 
transcriptional control of a human cytomegalovirus (HCMV) promoter in place of the unique 
short (US) region 3 through 8 genes of the HSV-1 genome, including the glycoprotein D (US6) 
gene (Figure 8)(2). K∆Us3-8Z was propagated and titered on VD60 cells and passaged through 
Vero cells to obtain gD-deficient virions. KHZ.1 is a KOS-derived virus containing an HCMV-
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 lacZ expression cassette in the thymidine kinase locus (115). QOZHG is a replication-defective 
derivative of KOS (19). This virus does not produce four of the immediate early proteins (ICP4, 
22, 27 and 47) due to deletions and substitutions in its genome. It contains the enhanced green 
fluorescent protein (EGFP) and β–galactosidase reporter genes, and is grown on ICP4 and 27 
complementing Vero-derived 7B cells (107). VSV expressing GFP was kindly provided by Dr. 
Patricia W. Dowling and Dr. Ira Bergman (University of Pittsburgh School of Medicine) and has 
been previously described (7). 
 
Figure 8. Construction of KΔUs3-8Z virus.  
LacZ gene under the HCMV promoter was inserted into the Us3-8 locus of KOS, replacing gD, 
as well as several other non-essential glycoproteins. 
3.2. Plasmids  
 
The HSV-1 SacI fragment containing the gD promoter and coding sequence was cloned into 
pSP72 (Promega, Madison, WI) and the resulting plasmid designated pgDSac.  
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 In order to create an expression plasmid for soluble gD, the transmembrane region was 
removed from pgDSac after amino acid 287 by digesting pgDSac with NarI and EcoRI and 
replacement of this segment with annealed complementary oligonucleotides specifying 6 
histidine residues followed by a stop codon (primer 1: 5’ CG CAC CAT CAC CAT CAC CAT 
TAG TTT AAA CGG GGG 3’; primer 2: 5’ A ATT CCC CCG TTT AAA CTA ATG GTG 
ATG GTG ATG GTG 3’). The truncated gD-His6 sequence was excised from a selected 
recombinant by digestion with HindIII and EcoRI and placed under transcriptional control of the 
HCMV promoter of expression vector pcDNA3.1+ (Gibco-Invitrogen, Carlsbad, CA). The 
resulting plasmid, psgD287, was confirmed by DNA sequencing. 
 Mutant L25P and R222N,F223I full-length gD constructs were generated in pgDSac 
using the Gene Editor in vitro site-directed mutagenesis kit (Promega). The mutants were 
authenticated by DNA sequencing and tested in a transient complementation assay for their 
ability to complement gD-deficient K∆Us3-8Z virus (Q. Bai, W. Ali Shah, J.B. Cohen, R.J. 
Eisenberg, G.H. Cohen and J.C. Glorioso. Abstr. 26th International Herpesvirus Workshop, abstr. 
2.10, 2001). In order to transfer the mutations from pgDSac to psgD287, an acceptor plasmid 
(psgD287∆) was first derived from psgD287 by deletion of an internal 216-bp BstZ17I-NaeI 
fragment. The desired mutations were then transferred from the pgDSac-based plasmids as 
HindIII-PpuMI fragments, restoring the deleted region in the acceptor plasmid. Recombinants 
were identified by digestion with FspI, which cuts in the deleted region and distinguishes 
between pgDSac and psgD287. 
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3.3. Purification of sgD Proteins   
 
293T cells were transfected with psgD287, psgD287(L25P) and psgD287(R222N,F223I) plasmids 
using LipofectAMINE-PLUS (Gibco-Invitrogen). After 3 days at 37°C, supernatants were 
collected and loaded onto ProBond (Gibco-Invitrogen) nickel-chelating columns for purification 
of the His-tagged proteins according to the manufacturer’s protocol.  Proteins were concentrated 
by using a Centricon YM-10 centrifugal filter device (Amicon, Bedford, MA) and dialyzed 
against PBS at 4°C overnight.   
The molecular weights of each protein were estimated by Western blot analysis. 15 μl of 
each protein were electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred 
to an ImmobilonTM PVDF membrane (Millipore, Billerica, MA). The membrane was blocked for 
1 h in 5% milk/PBST at room temp, then probed with polyclonal anti-gD antibody R7 (kindly 
provided by Drs. G.H. Cohen and R.J. Eisenberg, University of Pennsylvania) (92) and an anti-
rabbit HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA), or an 
anti-His HRP-conjugated antibody (Santa Cruz Biotechnology). The membrane was developed 
using Amersham ECL kit (Amersham, Piscataway, NJ). Protein concentrations were determined 
by Bradford assay (Bio-Rad, Hercules, CA). 
3.4. Transient gD-Complementation Assay 
 
Vero cells were seeded in a 6-well plate and were either mock-transfected or transfected with 
gDSacI using LipofectAMINE-Plus reagent (Gibco-Invitrogen). Cells were infected for 2 h at 
37ºC with gD-complemented KΔUs3-8Z at MOI=3 24 h after transfection, and then washed with 
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 0.1M glycine (pH 3.0) for 1 min at room temperature to deactivate extra-cellular virus. Virus was 
harvested 1 day post infection. The supernatant was discarded and the cells were scraped in a 
volume of 200 μl serum-free DMEM. Cells were sonicated and the cell debris was pelleted by 
low-speed centrifugation. CHO-nectin-1 cells were infected with 25 μl supernatant and CHO-
HVEM with 50 μl for 3 h. Infected cells were visualized after 24 h by X-gal staining.  
 
3.5. Detection of sgD Bound to CHO-HVEM Cells by Immuno-fluorescence  
 
Sub-confluent monolayers of CHO-HVEM cells in a 48-well plate were incubated with 1000 ng 
of sgD for 1 h at 37ºC. Cell were then washed and fixed with 2% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA) for 5 minutes at room temperature. Cells were then washed 
and incubated with a pool of anti-gD monoclonal antibodies at a 1:500 dilution (75) for 1 h at 
room temperature, washed, and incubated for another hour with an anti-mouse Cy3 conjugated 
secondary antibody (Sigma-Aldrich, St. Louis, MO), diluted 1:500. Cells were visualized with a 
Nikon diaphot TMS fluorescent microscope under a 20X magnification (Nikon, Melville, NY) 
and photographed with a Leica Microsystems AG DFC 300F digital camera. 
 
3.6. Flow Cytometry  
 
Mouse monoclonal antibody CK41 (92) at a 1:250 dilution was used to identify surface nectin-1 
in adherent cell cultures. Antibody binding and washes were performed at 4ºC in PBS containing 
1% horse serum (Gibco). Cell bound CK41 was detected using FITC-conjugated anti-mouse 
antibody (Sigma-Aldrich) and analyzed on a FACSCalibur (Becton-Dickinson, San Diego, CA). 
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3.7. Localization of sgD After Binding at 4ºC and Shifting to 37ºC  
 
sgD was incubated with confluent monolayers of CHO-HVEM cells for 2 h at 4ºC in a 24-well 
dish. The samples that included gD- KΔUs3-8Z were then washed, and incubated with the virus 
for an additional 1.5 h at 4ºC. Following the 4ºC incubation, cells were washed with cold buffer 
and either lysed right away or shifted to 37ºC for various amounts of time in the presence of 
37ºC F12 media containing aprotinin and leupeptin, and then lysed with 50 μl PARP buffer (6 M 
urea, 2% SDS, 10% glycerol, 62.5 mM Tris-HCl, pH 6.8, and 5% β-mercaptoethanol) (140) per 
well. At each time point duplicate wells were treated with 100 ug/ml TPCK-treated trypsin 
(Sigma-Aldrich) for 2.5 min at 37ºC before lysing, and the trypsin was quenched with 200 ug/ml 
soybean trypsin inhibitor (Sigma-Aldrich). Supernatant was collected from the cells that were 
shifted to 37ºC before lysis buffer was added. Each sample was sonicated for 20 sec with a 
Fisher Scientific 60 Sonic Dismembrator (Fisher Scientific, Hampton, NH) to break up the 
cellular DNA and prepared for Western blot analysis. 25 μl of each lysate and 25 μl of the 
supernatants were electrophoresed on a 10% SDS-polyacrylamide gel and the proteins were 
transferred to nitrocellulose membranes. The membranes were blocked for 1 h in 5% milk/PBS 
at room temperature, then probed with R7 polyclonal anti-gD antiserum at a 1:5,000 dilution in 
2% milk/PBS at 4ºC overnight, and the membrane was washed three times in PBS for 10 min 
each. Goat anti-rabbit HRP-conjugated secondary antibody (Santa Cruz Biotechnology) was then 
incubated with the membrane at a 1:2,000 dilution in 2% milk/PBS for 1 h at room temperature, 
membranes were washed three times in PBS for 10 min each, and developed using Pierce 
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Rockford, IL). 
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3.8. Detecting Bound Virus by Western Blot Analysis 
 
Virus (gD- KΔUs3-8Z or KHZ.1) was adsorbed to confluent monolayers of pgsA745-nectin-1, 
CHOK1 or CHO-HVEM cells in 24-well plate for 2 h at 4ºC, either in the absence or presence of 
1 μg sgD. The cells were washed with cold buffer and lysed immediately with 50 μl PARP 
buffer. Bound virus was detected by Western blot analysis. Each sample was sonicated for 20 sec 
with a Fisher Scientific 60 Sonic Dismembrator (Fisher Scientific, Hampton, NH) to break up the 
cellular DNA. 25 μl of each lysate was electrophoresed on a 10% SDS-polyacrylamide gel and 
the proteins were transferred to an ImmobilonTM PVDF membrane (Millipore, Billerica, MA). 
The membrane was blocked for 1 h in 5% milk/PBST at room temp, and bound virus was 
detected with NC1 polyclonal rabbit anti-VP5 antiserum (26) (kindly provided by Drs. G.H. 
Cohen and R.J. Eisenberg, University of Pennsylvania) at a 1:5,000 dilution in 5% milk/PBST at 
room temp for 1.5 h, followed by goat anti-rabbit HRP-conjugated secondary antibody (Santa 
Cruz Biotechnology) at a 1:2,000 dilution. Membranes were developed using Amersham ECL kit 
(Amersham). 
 As a control for the amount of protein loaded in each lane, membranes were re-probed 
with a mouse anti-actin monoclonal antibody (Chemicon International, Temecula, CA) at a 
1:5,000 dilution. 
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 3.9. Detection of KΔUs3-8Z Binding to pgsA745-nectin-1 Cells by Indirect Entry Assay  
 
gD- KΔUs3-8Z was adsorbed to confluent monolayers of pgsA745-nectin-1 cells in 48-well plate 
for 2 h at 4ºC, either in the absence of presence of 1000 ng sgD. The cells were washed with cold 
buffer, and 1000 ng sgD was added in 37ºC media to allow adsorbed virus to penetrate. Cells 
were infected at 37ºC for 3 h, sgD was replaced by media, and cells were stained with X-gal after 
16 h. 
3.10. Real-Time Quantitative PCR  
 
Viral preparations were quantified for the immediate-early gene ICP47.  All assays were 
conducted in 50 μL PCR volumes containing viral samples (2 μL), 200 nM of each primer, 200 
nM Probe, and 25 μL TaqMan® 2X Universal Master Mix (PE Applied Biosystems, Foster City, 
CA). Primer sequences for ICP47 (forward- CAC GAC ATG CTT TTC CCG A, and reverse- 
TTC CCG CAG GAG GAA CG), were designed using the Primer Express program (PE Applied 
Biosystems).  The TaqMan probe for detection of ICP47 (CGC CGG TCG CCT CGA CGA) was 
labeled with fluorescent reporter dye 6-carboxyfluorescein (6-FAM) at the 5’ end and the 
quencher dye carboxytetramethylrhodamine (TAMRA) at the 3’ end (PE Applied Biosystems).  
All PCR reactions were set up in a MicroAmp Optical 96-well Reaction Plate (PE Applied 
Biosystems).  Amplification conditions were 2 min at 50°C and 10 min at 95°C for the first 
cycle, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min.  The TaqMan probes were 
cleaved during the amplification of target sequence generating fluorescent emission specific for 
FAM-labeled probes.  All samples and standards were run at least in duplicate and each run 
contained several negative (reaction mix with no sample and a sample known to contain no HSV 
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 DNA) and positive controls (samples known to contain HSV sequences, a plasmid and a HSV 
vector).  Standards curves for viral gene ICP47 were generated using 10-fold serial dilutions of 
plasmids known to contain the respective target sequences. Efficiency of ICP47 primer-probe set 
was confirmed previously by side-by-side TaqMan PCR runs with other HSV genes of other 
KOS-derived viruses including ICP27 and gD that have been qualified by negative staining 
electron microscopy analysis.  The emission data was collected in real-time from an ABI 
PRISM® 7000 Sequence Detector System (SDS) and analyzed using Sequence Detector 
Software (PE Applied Biosystems).  
Each purified virus sample was diluted at in TE (10mM Tris-HCL, pH 7.5, 1mM EDTA) 
and filtered twice in sterile Pall® Acrodisc® 32 mm Syringe Filter with 1.2 μm Supor membrane® 
(Pall Life Sciences, East Hills, NY). Genomic DNA of each sample was isolated by using 
QIAamp® DNA Micro Kit (Qiagen Inc., Santa Clara, CA) using the conditions specified by the 
manufacturer. 
 
3.11. Calculation of the Relative Efficiency of sgD-Mediated Entry 
 
Using the TaqMan standard curves described above, the particle concentrations of our virus 
stocks were determined to be 8.39 ± 1.26 x 109/ml for gD- K∆Us3-8Z and 9.03 ± 1.91 x 1010/ml 
for gD-complemented K∆Us3-8Z. For each preparation, the transduction efficiency on CHO-
HVEM cells (particles/blue cells) was then established as approximately 1.1 x 103 for the gD- 
stock in the presence of sgD versus 1.1 x 102 for the gD-complemented stock. Thus, the 
difference in transduction efficiencies between the two stocks was estimated as approximately 
10-fold. 
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3.12. Treatment with Lysosomotropic Agents 
 
Stock solutions of ammonium chloride (1.5 M; Sigma-Aldrich) and chloroquine (50 mM; Sigma-
Aldrich) were prepared immediately prior to use. Monensin stock solution (75 mM; Sigma-
Aldrich) was prepared in ethanol and stored at -20ºC. Bafilomycin A1 (160 μM; Sigma-Aldrich) 
and concanamycin A (50 μM; Sigma-Aldrich) stock solutions were prepared in DMSO, 
aliquoted and stored at -20ºC. Cells in 96-well plates were pre-incubated with final 
concentrations of drugs for 30 min in a total volume of 30 μl F12 media. 3 μl virus was added 
per well, and cells were infected for 6-10 h at 37ºC in the presence of drug, depending on the 
virus used. Infected cells were detected by X-gal staining, ONPG assay or observation of EGFP 
expression. 
3.13. Trypsin Protection Assay 
 
QOZHG at MOI=50 was adsorbed to CHO-HVEM cells in a 48-well plate for 2 h at 4ºC. Cells 
were washed and either lysed immediately with PARP buffer (6 M Urea, 2% SDS, 10% glycerol, 
62.5 mM Tris-HCl pH 6.8, 5% β-mercaptoethanol) (140) (6 M urea, 2% SDS, 10% glycerol, 
62.5 mM Tris-HCl, pH 6.8, and 5% b-mercaptoethanol), or shifted to 37ºC for 10 or 30 min, and 
then lysed. Duplicate samples were treated with TPCK-trypsin (100 μg/ml) for 2.5 min after the 
10 or 30 min incubations. Trypsin was quenched with soybean trypsin inhibitor (200 μg/ml), 
cells were scraped, pelleted, and re-suspended in 50 μl PARP buffer per well. 
 The presence of glycoproteins in the lysates was detected by Western blot analysis. 30 μl 
of each sample were electrophoresed on a 10% SDS-polyacrylamide gel and the proteins were 
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 transferred to an ImmobilonTM PVDF membrane (Millipore, Billerica, MA). The membrane was 
blocked for 1 h in 5% milk/PBST at room temperature, then probed with R7 rabbit polyclonal 
antiserum  at a 1:5,000 dilution in 5% milk/PBST at room temp for 1.5 h, and the membrane was 
washed three times in PBST for 10 min each. Goat anti-rabbit HRP-conjugated secondary 
antibody (Santa Cruz Biotechnology) was then incubated with the membrane at a 1:2,000 
dilution for 1 h at room temperature in 5% milk/PBST, membrane was washed three times in 
PBST for 10 minutes each, and developed using Amersham ECL kit (Amersham). Afterwards, 
the membrane was stripped and re-probed with a pool of anti-gB monoclonal antibodies (1:5,000 
dilution (110) and again with anti-VP5 NC1 antibody (1:1,000 dilution). 
 
3.14. Proteinase K Protection Assay 
 
A stock solution of proteinase K (10 mg/ml) was prepared in Ham’s F12 medium, aliquoted, and 
stored at -20ºC. A stock solution of PMSF (100 mM) was prepared in ethanol, aliquoted and 
stored at -20ºC. KHZ.1 at MOI=20 was adsorbed to CHO-HVEM cells in a 24-well plate for 2 h 
at 4ºC. Cells were washed and either kept at 4ºC with serum-free media, or shifted to 37ºC for 10 
or 30 min, and then transferred to 4ºC with 4ºC serum-free media. Duplicate samples were 
treated with proteinase K (2 and 4 mg/ml) for 1 h at 4ºC, and proteinase K was quenched with 
PMSF (4 mM). Cells were scraped, pelleted, and re-suspended in 50 μl PARP buffer per well. 
 The removal of virus particles from the cell surface by proteinase K and internalization of 
glycoproteins was detected by Western blot analysis. 30 μl of each sample were electrophoresed 
on a 10% SDS-polyacrylamide gel and the proteins were transferred to an ImmobilonTM PVDF 
membrane (Millipore, Billerica, MA). The membrane was blocked for 1 h in 5% milk/PBST at 
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 room temperature, then probed with anti-VP5 NC1 antibody (1:5,000 dilution) in 5% milk/PBST 
at room temperature for 1.5 h, and the membrane was washed three times in PBST for 10 min 
each. Goat anti-rabbit HRP-conjugated secondary antibody (Santa Cruz Biotechnology) was then 
incubated with the membrane at a 1:2,000 dilution for 1 h at room temperature in 5% 
milk/PBST, membrane was washed three times in PBST for 10 min each, and developed using 
Amersham ECL kit (Amersham).  
3.15. Rate of Entry of gD- KΔUs3-8Z in the Absence of sgD 
 
gD- KΔUs3-8Z was adsorbed to CHO-HVEM cells for 2 h at 4ºC. Cells were washed and 500 ng 
sgD was either added immediately or after various amounts of time that the cells were incubated 
at 37ºC in the absence of sgD. The degree of infection was quantified by ONPG 16 h after 
infection. The amount of internalized virus in the absence of sgD was extracted from the 
observed decrease in entry over time, since gD- virus was shown to be non-infectious in the 
absence of sgD. 
3.16. Rate of Entry of gD- KΔUs3-8Z in the Presence of sgD  
 
gD- KΔUs3-8Z was adsorbed to CHO-HVEM cells for 2 h at 4ºC. Cells were washed and 500 ng 
sgD in 37ºC media was added to each well. Cells were shifted to 37ºC, and wells were treated 
with 0.1M glycine after various amounts of time to neutralize virus that had not yet been 
internalized. The degree of infection was quantified by ONPG 16 h after infection. 
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4. CHARACTERIZATION OF SOLUBLE GLYCOPROTEIN D MEDIATED 
ENTRY OF gD-DEFICIENT HSV 
 
4.1. Soluble gD Mediates Entry of a gD-Deficient Virus into HSV Receptor-Expressing 
Cells 
 
To determine whether glycoprotein D has the ability to mediate HSV entry when taken out of the 
context of the viral envelope, a soluble form of gD (sgD) was generated by truncation of the 
ectodomain after amino acid 287 (Figure 9), and the ability of this protein to induce entry of the 
gD-deficient virus K∆Us3-8Z (2) was examined. Virions lacking gD were produced by infection 
of Vero cells with gD-complemented K∆Us3-8Z, removal of extracellular virus, and collection 
of cell lysates 3-5 days later.  
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Figure 9. Construction of soluble gD287.  
sgD287 was constructed by truncating the full-length gD after amino acid 287. This construct 
comprises the critical functional region of the gD ectodomain, which is necessary and sufficient 
for HSV entry. 
 
Soluble gD proteins used in this study were prepared by transfection of 293T cells with 
suitable mammalian expression constructs and recovery of the histidine-tagged products by 
passage of the growth media over Ni2+ affinity columns. Each purified protein was detected at a 
molecular size of approximately 38kD on Western blots using a His tag-specific antibody 
(Figure 10).  
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Figure 10. Western blot analysis of purified soluble gD proteins. 
His-tagged wild-type (wt) and mutant sgD proteins were purified as described in Materials and 
Methods, and electrophoresed on a 10% SDS polyacrylamide gel. Proteins were detected with an 
anti-His HRP-conjugated antibody. Wild type and mutant sgD proteins were detected at a 
molecular size of approximately 38kD. 
 
To assay sgD for its ability to mediate entry of gD-deficient K∆Us3-8Z, CHO-K1 cells 
and derivative lines expressing HVEM or nectin-1 were incubated for 3 h with the virus in the 
presence of the soluble protein. Entry was visualized 16 h later by staining of the cells for β-
galactosidase activity expressed by the virus. Figure 11 demonstrates that sgD enabled entry of 
the gD-deficient virus into CHO-HVEM and CHO-nectin-1 cells, but not CHO-K1 cells. The 
degree of infection increased linearly with both the virus dose and the amount of sgD used 
(Figure 12). sgD-mediated infection of CHO-nectin-1 cells was less efficient than infection of 
CHO-HVEM cells, a finding that did not correlate with the relative susceptibility of these two 
cell lines to infection by virus harboring gD in its envelope (Figure 13). 
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Figure 11. sgD (wt) mediates entry of gD-deficient virions into receptor-bearing cells. 
Confluent monolayers of CHO-HVEM (a and b), CHO-nectin-1 (c and d) and CHO-K1 (e and f) 
cells in 96-well plates were incubated with gD-deficient K∆Us3-8Z virus, which contains the 
lacZ gene driven by the HCMV promoter (2), in the presence or absence of 500 ng sgD for 3 
hours at 37ºC. Infected cells were identified by X-gal staining 16 hours after infection. 
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Figure 12.  sgD and virus dose dependence of sgD-mediated infection. 
CHO-HVEM cells were infected using 1 μl gD-deficient KΔUs3-8Z and varying amounts of sgD 
(A) or gD-deficient KΔUs3-8Z in the presence of 500 ng sgD (B). Entry was quantified by 
measuring β-galactosidase activity using the ONPG assay. 
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Figure 13. Infection of CHO-HVEM and CHO-nectin-1 cells by gD-complemented KΔUs3-
8Z. 
Virus was produced by infecting mock- or gD(wt)-transfected Vero cells with gD-complemented 
KΔUs3-8Z at MOI=3 and harvesting lysates 24 h post infection. a, b) CHO-HVEM cells were 
infected with 50 μl out of a total of 200 μl lysate. c, d) CHO-nectin-1 cells were infected with 25 
μl lysate. Infected cells were visualized by X-gal staining 16 h post infection. The number of 
infected cells was comparable on CHO-HVEM and CHO-nectin-1 cells. 
 
 
4.2. Determining the Efficiency of sgD-Mediated Entry 
 
Given the requirement for three components in sgD-mediated infection compared to two in 
normal infection, it was anticipated that sgD-mediated infection would be substantially less 
efficient than normal infection. To determine the relative efficiency of sgD-mediated infection 
versus infection by gD-containing gD virus, quantitative TaqMan PCR was used to estimate the 
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 number of virus particles needed in each case to produce a given number of transduced CHO-
HVEM cells (see Materials and Methods). The results showed a 10.6 fold reduction in 
transducing events per viral particle for gD-deficient K∆Us3-8Z in the presence of sgD 
compared to a K∆Us3-8Z preparation harvested from gD-complementing VD60 cells.  Thus it 
was estimated that the efficiency of sgD-mediated infection is approximately one order of 
magnitude lower than that mediated by virion gD. 
 
4.3.  sgD-Mediated Entry of gD-Deficient HSV Requires Specific Interaction with a gD 
Receptor 
HSV-1 entry into cells depends on the interaction of virion gD with a cognate cell-surface 
receptor. To confirm that sgD-mediated entry of gD-deficient virus likewise required a specific 
interaction between sgD and a cognate receptor, receptor-specific mutant versions of the soluble 
protein were tested. The L25P mutation in gD impairs virus entry through HVEM without 
diminishing entry via nectin-1 (197).  In addition, a rare gD mutant that is defective for binding 
and entry via nectin-1 but competent for binding and entry via HVEM was previously isolated in 
our laboratory [gD(R222N,F223I)] (Q. Bai, W. Ali Shah, J.B. Cohen, R.J. Eisenberg, G.H. 
Cohen and J.C. Glorioso. Abstr. 26th International Herpesvirus Workshop, abstr. 2.10, 2001). To 
determine whether these mutations affected sgD-mediated infection, sgD(L25P) and 
sgD(R222N,F223I) were prepared and tested for their ability to mediate entry of gD-deficient 
K∆Us3-8Z into gD-receptor bearing cells. As shown in Figure 14, sgD(L25P) displayed a 
substantially reduced ability to mediate entry into CHO-HVEM cells (compare panels c and e) 
while its ability to mediate entry into CHO-nectin-1 cells was unaltered, if not enhanced, 
compared to wild-type sgD (panels d and f). Conversely, sgD(R222N,F223I) mediated entry into 
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 CHO-HVEM, but not CHO-nectin-1 cells (panels g and h). These results supported the 
conclusion that sgD-mediated entry of gD-deficient virus involves specific interaction of the 
soluble mediator with a cognate cellular receptor, similar to virion gD interaction with a cognate 
receptor during normal infection.  
 
Figure 14. sgD-mediated entry of gD-deficient HSV requires specific interaction of sgD 
with a gD receptor. 
gD-deficient K∆Us3-8Z was incubated with CHO-HVEM and CHO-nectin-1 cells in the absence 
of sgD (a and b) or in the presence of wild type sgD (c and d), sgD (L25P) (e and f), or sgD 
(R222N,F223I) (g and h) for 3 h at 37°C. Infected cells were identified by X-gal staining 16 
hours after infection. 
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5. Mechanistic Aspects of sgD-Mediated Entry 
 
The availability of a functional 3-component system presented the opportunity to investigate the 
order of interactions between gD, the receptor and the other virion glycoproteins. We asked if 
sgD first needs to bind to its cell-surface receptor in order to function as a stable receptor for the 
gD- HSV virion. According to the current model for HSV entry, gD undergoes a conformational 
change upon receptor binding, which allows it to interact with another virion glycoprotein and 
thereby initiate the fusion cascade Our experiments were designed to determine whether this 
conformational change is of a stable or transient nature. 
CHO-HVEM cells were incubated with sgD for 1 h at 37oC, washed several times to 
remove free sgD, and exposed to gD-deficient K∆Us3-8Z at 37oC. The results showed that 
infection was reduced to background levels under these conditions (Figure 15C), compared to 
readily detectable infection when sgD and the virus were added to the cells either simultaneously 
(Figure 15B) or in the reverse order (Figure 15D).  Washing the cells prior to the addition of gD-
deficient virus did not remove adsorbed sgD since cell-associated sgD was clearly observed at 
this stage by immuno-fluorescence using a pool of monoclonal anti-gD antibodies (75) (Figure 
15F). These results suggested that sgD may undergo a transient conformational change and fall 
back to an inactive state before virus accumulation at the cell surface is adequate for sgD-
mediated entry. 
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sgD 1 h 37ºC, 
wash, fix, IF 
Figure 15. Mechanistic requirements of sgD-mediated entry. 
Entry of gD- K∆Us3-8Z virus was assayed on CHO-HVEM cells under various conditions, and 
sgD binding to the cells was examined by immunofluoresence. (A) Cells were incubated with 
gD- K∆Us3-8Z alone at 37ºC for 3 h. (B) sgD and gD- K∆Us3-8Z were added to cells 
simultaneously and incubated with the cells for 3 h at 37ºC. (C) Cells were pre-incubated with 
sgD at 37ºC for 1 h, washed, and incubated with gD- K∆Us3-8Z for 3 h. (D) Cells were pre-
incubated with K∆Us3-8Z for 1 h at 37ºC, washed, and incubated with sgD at 37ºC for 3 h. (E, F 
CHO-HVEM cells were incubated for 1 h at 37ºC without (E) or with sgD (F), the cells were 
washed with buffer and then fixed for 5 min with 2% paraformaldehyde, and sgD was detected at 
the cell surface by sequential incubation with a pool of monoclonal anti-gD antibodies (75) and 
Cy3-conjugated anti-mouse secondary antibody. 
 
 
 
To test this interpretation, sgD binding to the cells was performed at 4ºC in an attempt to 
separate receptor binding from secondary events, such as conformational changes, tha may occur 
only at 37ºC. After removal of free sgD with cold buffer, gD-deficient virus was added to the 
 57
 monolayer and the cells were shifted to 37ºC for the usual 3 h infection. By this protocol, 
infection remained much lower than following simultaneous addition of virus and sgD (Figure 
16, compare A and B). This result was consistent with instability of the receptor-induced active 
conformation of sgD, diminishing the availability of the active form prior to abundant virus 
adsorption to the cells. To determine whether saturated virus attachment preceding the shift to 
37ºC would restore entry, we incubated the cells sequentially with sgD and gD-deficient K∆Us3-
8Z at 4ºC, washing after each incubation, and then raised the temperature to 37ºC. Under these 
conditions, the infection level approached that observed after simultaneous addition of virus and 
sgD (Figure 16, compare A and C). Together, these results indicated that sgD binding to HVEM 
produces a receptor for gD-deficient virus that is unstable at 37oC. Our results do not show 
whether this receptor requires the increased temperature to assume its active state, but they do 
suggest that this active state is short-lived at the higher temperature. 
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Figure 16. Pre-adsorption of gD- K∆Us3-8Z to CHO-HVEM cells pre-incubated with sgD 
improves infection efficiency. 
(A) sgD and gD- K∆Us3-8Z were added to CHO-HVEM cells simultaneously and incubated with 
the cells for 3 h at 37ºC. (B) Cells were pre-incubated with sgD for 2 h at 4ºC and then washed to 
remove unbound sgD. gD- K∆Us3-8Z was added and the cells were incubated at 37ºC for 3 h. 
(C) Cells were pre-incubated with sgD for 2 h at 4ºC, washed, and incubated with gD- K∆Us3-
8Z for an additional 2 h at 4ºC. The cells were then washed again and shifted to 37ºC for 3 h. 
After the 3 h infection period, fresh media was added to all wells, and the cells were X-gal 
staining 16 h later. 
 
 
To determine the inactivation kinetics of receptor-bound sgD, we shifted the cells to 37ºC 
for various times between the sgD and virus adsorption steps performed at 4oC. Our results 
showed that entry was diminished after 5 min at 37ºC, and completely eliminated after 30 min 
(Figure 17). Thus, the inactivation was not instantaneous, as would be expected for an 
inactivating conformational change, suggesting that the receptor-bound, active conformation of 
sgD was stable at the infection temperature. Thus, we hypothesized that other processes were 
responsible for the decreasing activity of pre-bound sgD at 37oC, such as internalization of the 
sgD-receptor complex, sgD dissociation, or degradation at the cell surface. 
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Figure 17.  Time required for sgD inactivation.  
CHO-HVEM cells were pre-incubated with sgD for 2 h at 4ºC, the cells were washed, and either 
gD- virus was added right away and incubated with the cells for 2 h at 4ºC (A), or the cells were 
shifted to 37ºC for 5 (B), 15 (C) or 30 min (D), and then incubated with the virus for 2 h at 4ºC. 
All cells were shifted to 37ºC to allow for infection. 
 
 
To explore these options, we determined whether sgD binding to the cells was stable at 
37ºC in the absence of excess sgD in the media. CHO-HVEM cells were incubated with sgD for 
2 h at 4ºC and washed to remove free sgD. The cells were then either fixed immediately (Figure 
18A), or shifted to 37ºC for 30 min and then fixed (Figure 18B). Cell-associated sgD was 
detected by immuno-fluorescence using a pool of monoclonal anti-gD antibodies (75). The 
results showed a dramatic reduction in signal following incubation at 37ºC (Figure 18B). The 
same phenomenon was observed using CHO-nectin-1 cells, demonstrating that the effect was not 
limited to HVEM-bound sgD (Figure 18C and D).  
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igure 18.  Detection of cell-surface-associated sgD after  incubation at 37ºC. 
D was bound to CHO-HVEM (A and B) or CHO-nectin-1 (C and D) cells at 4ºC for 2 h. Cells 
immediately (A and C) or shifted to 37ºC for 30 
in and then fixed (B and D). Receptor-bound sgD was detected at the cell surface with a pool 
f monoclonal anti-gD antibodies (75), as described earlier. 
In light of recent evidence showing endocytic HSV uptake into CHO cells (126, 128), we 
ere interested in distinguishing whether the observed loss of cell-associated sgD at 37oC could 
e ascribed to receptor-mediated endocytosis or to other processes, such as proteolytic 
egradation at the cell surface or dissociation from the cognate receptor in the absence of 
bundant free sgD. To this end, CHO-HVEM cells were incubated with sgD at 4ºC for 2 h, free 
immediately or after incubation at 37ºC for 10 
F
sg
were washed with cold buffer, and either fixed 
m
o
 
 
w
b
d
a
sgD was removed, and the cells were lysed either 
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 or 30 minutes. Duplicate samples were treated in succession with trypsin and soybean trypsin 
hibitor prior to cell lysis to enable identification of internalized sgD. Western blot analysis 
sing gD-specific antibodies showed a loss of cell-associated sgD over time (Figure 19A, lanes 
, 6, 10). Trypsin effectively removed all sgD from the cell surface (Figure 19A, lane 4), and no 
e 19C, compare lanes 2 and 4). To 
etermine whether the loss of cell-surface sgD over time could be attributed to dissociation from 
the rece
in
u
2
trypsin-resistant material was detected at either the 10- or 30-min time points (Figure 19A, lanes 
8 and 12); in separate experiments, the effectiveness of soybean trypsin inhibitor in eliminating 
all trypsin activity prior to cell lysis was confirmed (Figur
d
ptor, media samples were included in the Western blot analysis of Figure 19A (lanes 14, 
15). sgD was detected in both samples, each representing one-eighth of the total supernatant at 
the given time point. Judging from a separate experiment using TCA precipitation to collect sgD 
from the entire supernatant, the amount of sgD released into the media after 30 min at 37oC was 
approximately equal to the amount of cell-associated sgD at the start (Figure 19B, compare lanes 
1 and 3). These results demonstrated that sgD dissociated from the HVEM receptor after excess 
sgD was removed from the media, thereby providing a satisfactory explanation for the 
observation that pre-bound sgD could mediate entry of pre-attached virus, but not of virus that 
was added at the infection temperature.  
To test whether the presence of gD-deficient KΔUs3-8Z would either stabilize sgD at the 
cell-surface or cause its internalization, gD- virus was included at each of the time points 
described above. The amount of gD- virus applied to the wells was the same as that normally 
used for infection of CHO-HVEM cells and was more than sufficient to detect bound virus by 
immunofluorescence using a pool of monoclonal anti-gC antibodies (76) (Figure 20). Our results 
showed that sgD was not detected in the interior of the cell in the presence of the virus (Figure 
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 19A lanes 9 and 13). In addition,  sgD was not detectably stabilized at the cell surface in the 
presence of virus (Figure 19A, lanes 7 and 11).  
 
 
 
A 
 
 
B C 
Figure 19.  sgD localization. 
(A) sgD was bound to CHO-HVEM cells for 2 h at 4ºC either alone (lanes 2, 4, 6, 8, 10 and 12) 
or in the presence of gD-deficient virus (lanes 3, 5, 7, 9, 11 and 13). Cells were washed with cold 
buffer and either lysed immediately (lanes 1-5) or incubated with fresh, pre-warmed media at 
37ºC for 10 (lanes 6-9) or 30 min (lanes 10-13) before lysis. To identify internalized sgD (lanes 
4, 5, 8, 9, 12 and 13), cell-bound sgD was removed with 100 ug/ml TPCK trypsin, followed by 
quenching with soybean trypsin inhibitor, prior to cell lysis. Supernatants were collected from 
reactions 6 and 10 at the end of the 37ºC incubation period (10 and 30 min, respectively), and a 
fraction (1/8th) of each was loaded on the gel (lanes 14 and 15). Lysate from CHO-HVEM cells 
without sgD or virus was applied as a control (lane 1). (B) sgD was bound to CHO-HVEM cells 
for 2 h at 4ºC. The cells were then washed and lysed either immediately (lane 1) or after 
incubation at 37ºC for 30 min with fresh, pre-warmed medium (lane 2). The medium was 
ollected at the end of the 37ºC incubation and its protein content precipitated with TCA (lane 3). c
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 (C) sgD was adsorbed to CHO-HVEM cells for 2 h at 4ºC, and the cells were washed with cold 
buffer to remove unbound sgD. Lane 1, cells were collected by scraping and centrifugation, and 
resuspended in lysis buffer. Lane 2, trypsin (100 μg/ml) and soybean trypsin inhibitor (SBTI, 
200 μg/ml) were added to the cells simultaneously before collecting the cells. Lane 3, lysate of 
CHO-HVEM cells without sgD. Lane 4, CHO-HVEM cells pre-incubated with sgD, as above, 
were incubated with trypsin in pre-warmed medium at 37ºC for 2.5 min. SBTI was then added, 
and the cells were collected and resuspended as above. 
 
 
 
    
A B
 
 
Figure 20. Detection by gC antibodies of gD- virus bound to CHO-HVEM cells. 
gD-deficient KΔUs3-8Z was adsorbed to CHO-HVEM cells for 2 h at 4ºC. Cells were then 
washed with cold media to remove unbound virus, and fixed with 2% paraformaldehyde. Bound 
virus was detected by incubation with a pool of anti-gC monoclonal antibodies (B) (76) followed 
by anti-mouse Cy3 conjugated secondary antibody. Cells alone, incubated with the same 
antibodies, were used as a control (A). 
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6. The Role of GAGs in sgD-Mediated and Wild-Type Virus Entry 
 
6.1. sgD- Mediated Entry into GAG-Deficient Cells 
 
Since gD-deficient HSV is unable to bind to cells through the gD-receptor interaction, we 
expected that the presence of GAGs at the cell surface would be an absolute requirement for the 
purpose of virus attachment in sgD-mediated entry. To test this suggestion, a GAG-deficient cell 
line expressing nectin-1 (pgsA745-nectin-1) was generated. This line was derived by stable 
transfection of pgsA745 cells, a CHO mutant line that is defective in GAG synthesis (39), with a 
nectin-1 expression plasmid. Flow-cytometry analysis using nectin-1-specific monoclonal 
antibody CK41 (92) confirmed the presence of nectin-1 on the surface of pgsA745-nectin-1 cells. 
Quantitative analysis further demonstrated that the proportion of cells expressing surface nectin-
1 was substantially greater for the pgsA745-nectin-1 line than for the GAG-expressing CHO-
nectin-1 line used in earlier parts of our study (Figure 21A and B).  In addition, pgsA745-nectin-
1 cells expressed more surface nectin-1 per cell than their CHO-nectin-1 counterparts.  
To examine the HSV susceptibility of this new cell line, a virus that had the full 
complement of envelope glycoproteins, including gD, was used. KHZ.1 is a KOS-derived virus 
containing a lacZ reporter gene in the thymidine kinase (tk) locus (115). The results showed that 
GAG+ CHO-nectin-1 cells were substantially more susceptible to KHZ.1 infection than 
pgsA745-nectin-1 cells (Figure 21C and D), consistent with the well-documented finding that 
efficient HSV infection depends on virus attachment to cell-surface GAGs (3, 62, 70, 71, 96, 
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 166). These results suggested that elevated nectin-1 levels do not fully compensate for the 
bsence of GAGs in HSV infection. a
 
Figure 21. Characterization of pgsA745-nectin-1 cells. 
CHO-nectin-1 (A) and pgsA745-nectin-1 (B) cells were incubated with CK41 monoclonal 
antibod
cell line were quantified by flow cytometry. Entry of a KOS-derived virus containing a lacZ 
nectin-1 (D) cells by infecting cells for 2 hours at 37ºC at an MOI of 1. Infected cells were 
 
We next tested the ability of gD-deficient K∆Us3-8Z to enter the GAG-deficient 
pgsA745-nectin-1 cells in the presence of sgD was tested. Remarkably, pgsA745-nectin-1 cells 
were permissive for sgD-mediated entry despite the absence in this system of any known 
y at 4ºC, followed by an anti-mouse FITC conjugated antibody. Receptor levels on each 
expression cassette in the tk locus, KHZ.1 (115), was tested on CHO-nectin-1 (C) and pgsA745-
visualized by X-gal staining 16 hours post infection. 
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 mechanism for virus attachment (Figure 22C and D). Moreover, infection was typically more 
abundant with these GAG-deficient cells than with the GAG-expressing CHO-nectin-1 line 
(Figure 22, compare D and F). One possible explanation for the increased susceptibility of our 
pgsA745-nectin-1 cells to sgD-mediated infection is the elevated levels of nectin-1 on these 
cells, perhaps suggesting a greater role for the gD receptor in sgD-mediated infection than in 
infection utilizing virion gD. 
 
Figure 22. sgD-mediated infection of GAG-deficient pgsA745-nectin-1 cells. 
6.2. Binding of gD-Deficient Virus to GAG-Deficient Cells 
gD-receptor-deficient pgsA745 (A and B), pgsA745-nectin-1 (C and D), and CHO-nectin-1 (E 
and F) cells were infected with gD-deficient K∆Us3-8Z virus in the presence or absence of sgD 
for 3 h at 37°C. Entry was detected by X-gal staining the cells after 16 h. 
 
 
The unexpected occurrence of virus entry in the absence of GAGs and virion gD suggested that 
virus attachment to the cell could take place independent of the known virus binding 
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 mechanisms. We sought to determine whether this phenomenon reflected (i) the formation by 
sgD of an attachment bridge between virion glycoproteins and cell-surface receptors, specifically 
nectin-1, or (ii) a novel binding interaction between the virus and cell that was independent of 
gD or GAGs. To discriminate between these two possibilities, the amount of gD-deficient virus 
bound to pgsA745-nectin-1 cells was measured by Western blot analysis. The cells were 
incubated with gD-deficient K∆Us3-8Z for 2 h at 4ºC in the presence or absence of sgD, washed 
to remove unbound virus and sgD, and lysed. Western-blot probing with NC1 antibody reactive 
with the major capsid protein VP5 (26) revealed cell-associated virus (Figure 23A, lane 3), 
implying a previously unknown binding interaction. The presence of sgD did not detectably alter 
the amount of bound virus (lane 2), indicating that sgD interaction with its receptor did not 
significantly contribute to virus binding at 4oC. These results suggested that sgD-mediated 
infection of pgsA745-nectin-1 cells involved an sgD-independent binding step utilizing a novel 
interaction between the virus and cells. 
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Figure 23. Binding of gD-deficient KΔUs3-8Z virus to GAG-deficient pgsA745-nectin-1 
cells. 
pgsA745-nectin-1 cells were incubated with gD-deficient  KΔUs3-8Z alone (lane 3) or in the 
blot using anti-VP5 antibody NC1 (26). A prominent, non-specific cellular band is shown as a 
 
 
presence of sgD (lane 2) at 4°C for 2 h. Cells were then washed, lysed and analyzed by Western 
loading control. 
 
6.3. Characterization of the Novel Binding Interaction 
ine whether the ability to bind GAG-deficient cells was unique to gD-deficient HSV, 
ount of gD-deficient KΔUs3-8Z and KHZ.1 bound to GAG+ and GAG- cells was 
determined. KHZ.1 was adsorbed to pgsA745, pgsA745-nectin-1, CHO-K1 and CHO-nectin-1 
cells at 4ºC for 2 h, unbound virus was removed, and cell lysates were analyzed by Western blot 
using anti-VP5 antibody. The results showed that virus containing envelope-anchored gD, like 
gD-deficient virus, bound to GAG-deficient pgsA745 cells (Figure 24A, lane 3), although much 
less abundantly than to GAG-containing CHO-K cells (Figure 24A, lanes 1 and 2). KHZ.1 
binding to nectin-1 expressing pgsA745-nectin-1 cells was improved over binding to nectin-1 
 
To determ
the am
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 deficient pgsA745 cells (Figure 24A, compare lanes 3 and 4), demonstrating that the nectin-1-gD 
interaction does play a role in virus attachment in the absence of GAGs, although not clearly in 
the presence of GAGs (Figure 24A, compare lanes 1 and 6 or lanes 2 and 5). In agreement with 
the KHZ.1 entry data (Figure 21), the amount of KHZ.1 bound to nectin-1 bearing pgsA745 cells 
was lower than the amount bound to GAG-expressing CHO-K1 cells (Figure 24A, compare lanes 
1 and 4), showing that elevated levels of nectin-1 do not compensate for the absence of GAGs in 
HSV binding. 
Since sgD-mediated entry was not affected by the absence of cell-surface GAGs, the 
escribed above. The results showed that the presence of cell-surface GAGs did contribute to the 
inding of gD-deficient virus (Figure 24B, compare lanes 1 and 2, lanes 3 and 4). Thus, the 
comparable levels of sgD-mediated entry into GAG+ and GAG- nectin-1 expressing cells could 
virus binding. Interestingly, the ratio of virus bound to CHO-K1 
amounts of gD-deficient virus bound to GAG+ and GAG- cells were compared. gD-deficient 
KΔUs3-8Z was adsorbed to GAG-deficient pgsA745 and pgsA745-nectin-1 cells and to GAG-
expressing CHO-K1 and CHO-nectin-1 cells. Bound KΔUs3-8Z was detected by Western blot as 
d
b
not be attributed to equal 
compared to pgsA745 appeared to be much higher for KHZ.1 than for gD-deficient KΔUs3-8Z 
(Figure 24A, compare lanes 1 and 3, with Figure 24B, lanes 1 and 2). It is uncertain whether this 
difference reflects increased binding of gD-deficient KΔUs3-8Z to pgsA745 cells compared to 
KHZ.1, decreased binding to CHO-K1 cells, or a combination of these two factors.  
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Figure 24. Comparison of KHZ.1 and gD  KΔUs3-8Z binding to GAG-deficient and GAG-
expressing cells. 
CHO-K1 (lanes 1 and 2 in A, lane 1 in B), pgsA745 (lane 3 in A, 2 in B), pgsA745-nectin-1 
(lane 4 in A, 3 in B) and CHO-nectin-1 (lanes 5 and 6 in A, 4 in B) cells were incubated with 
gD
-
4ºC for 2 h (panel D) prior to the removal of free virus and infection at 37oC in the presence of 
sgD. Entry was marginally increased when sgD was included in the virus-binding step at 4ºC 
(panel E), and somewhat further enhanced when fresh sgD was additionally included at the 37ºC 
infection stage (panel F). These results suggested that gD-deficient virus that is bound to GAG-, 
+ KHZ.1 at MOI=100 (A) or gD- KΔUs3-8Z (B) for 2 h at 4ºC. The cells were then washed to 
remove un-bound virus, lysed, and analyzed by Western blot. Bound virus was detected by 
probing membranes with the anti-VP5 antibody NC1 (26). 2/5th of the total lysate was loaded in 
lanes 1 and 6 and 1/10th in lanes 2 and 5 of gel A. ½ of the total lysate was loaded in all the other 
lanes. Β-actin was used as a loading control. 
 
 
 To test the role of the GAG- and gD-independent cell association of gD-deficient virus in 
sgD-mediated infection, we examined whether virus entry could be observed when the binding 
and entry steps were separated. As shown in Figure 25, entry was severely reduced when gD-
deficient virus was incubated with pgsA745-nectin-1 cells at either 37ºC for 1 h (panel C) or at 
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 nectin-1 expressing cells through the novel binding interaction becomes rapidly unavailable to 
interact with sgD that is added subsequently.  
 
Figure 25.  Role of novel binding interaction in entry of gD-deficient KΔUs3-8Z. 
sgD-mediated entry into pgsA745-nectin-1 cells was analyzed under various conditions. (A) 
Virus alone was added to cells for 3 h at 37ºC. (B) Virus and sgD were added together for a 3 h 
infection period at 37ºC. (C) Virus was pre-incubated with cells for 1 h at 37ºC, cells were 
washed, and sgD was added for 3 h at 37ºC. (D) Virus was adsorbed to cells at 4ºC for 2 h, 
nbound virus was removed by washing the cells with cold buffer, and sgD was addeu d for 3 h at 
7ºC. (E) Virus was adsorbed to cells in the presence of sgD for 2 h at 4ºC, cells were washed, 3
and shifted to 37ºC for 3 h. (F) Virus was adsorbed to cells in the presence of sgD for 2 h at 4ºC, 
cells were washed, and fresh sgD was added to the cells for 3 h at 37ºC. Infected cells were 
identified by X-gal staining 16 h after infection. 
 
 
 We hypothesized that these observations may be due to a less stable nature of the novel 
binding interaction, when compared to the virus interaction with cell-surface GAGs. To 
investigate this hypothesis, the dissociation of gD-deficient KΔUs3-8Z from CHO-HVEM cells 
and pgsA745-nectin-1 cells was compared. gD-deficient KΔUs3-8Z was adsorbed to the cells at 
4ºC for 2 h, unbound virus was removed and the cells were either lysed immediately or shifted to 
37ºC for 10 or 30 min and then lysed. The amount of virus associated with the cells was 
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 determined by Western blot analysis as described above. Virus associated with the GAG-
deficient cells decreased gradually over time at 37ºC (Figure 26B)  while the amount of virus 
associated with GAG-expressing cells remained constant (Figure 26A). To determine whether 
this difference could also be observed with virus containing envelope-anchored gD, the 
experiment was repeated with KHZ.1 using CHO-K1 and pgsA745 cells. The results were 
similar to those obtained with gD-deficient virus (Figure 26C and D), demonstrating that binding 
through the novel binding interaction is less stable than GAG-mediated binding of HSV.  
  
 
 
 
 
Figure 26. Stability of the novel binding interaction.  
CHO-HVEM (A), pgsA745-nectin-1 (B), CHO-K1 (C), and pgsA745 (D) cells were incubated 
with gD-deficient  KΔUs3-8Z (A and B) or KHZ.1 at MOI=100 (C and D) for 2 h at 4ºC, washed 
to remove un-bound virus, and either lysed immediately (lanes 1) or shifted to 37ºC for 10 (lanes 
2) or 30 min (lanes 3), and then lysed. ½ of all the lysates were analyzed by Western blot. 
Membranes were probed with anti-VP5 NC1 antibody to identify the amount of bound virus in 
each sample, and with anti-β-actin as a loading control. 
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 7. ENDOCYTOSIS  
 
 
As stated earlier, several studies have recently presented evidence suggesting that HSV entry into 
certain cell types, including CHO cells, occurs through endocytosis (56, 119, 125, 126, 128). 
These studies suggested that HSV infection of CHO cells occurs through a pH-dep
7.1. Introduction 
 
endent 
otropic drugs inhibit productive infection, while 
in which the original HSV entry pathway studies were conducted, was not 
ffected (126, 128). In one study, Nicola et al. showed that internalization into CHO cells does 
). Since a gD-receptor is required for productive 
infection of these cells, these authors hypothesized that the receptor is required for release of 
virus from the endocytic compartment. In light of these observations, we wished to determine 
whether the pathway of sgD-mediated entry into CHO cells was different from that used by gD-
containing virus with the aim of gaining a better understanding of the role of gD in endocytosis 
and fusion at the cell surface or endosomal membrane. 
 
7.2. Results 
26, 128) that productive HSV infection of CHO 
endocytic pathway by showing that lysosom
entry into Vero cells, 
a
not require the presence of a gD-receptor (128
 
7.2.1. Inhibition with lysosomotropic agents 
 
As the first step in our investigation of the sgD-mediated entry pathway, we attempted to 
reproduce the observations of Nicola et al. (1
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 cells is blocked by lysosomotropic  recombinant viruses that contain 
nvelope anchored gD were tested [KHZ.1, the replication-defective recombinant QOZHG, and 
gD-complemented KΔUs3-8Z] for the effects of NH onensin, using the same protocol 
Nicola et al. (126). Cells were pre-incubated with the drugs, 
hloroquine did not inhibit entry of any of 
e viruses tested into either cell line. Numerous conditions were tested, including various drug 
concentrations, pre-incubation times, glycine treatment after infection, pH adjustments, and 
inclusion of serum, none of which improved th ucibility of these experiments. J1.1-
-1 cells created in our laboratory were also extensively tested. A similar line that was 
created in the laboratory of G. Campadelli-Fiume is reportedly resistant to inhibition by 
lysosomotropic agents and is infected by HSV via fusion at the cell surface (56). As with CHO-
HVEM and Vero cells,  inconsistent results were obtained with our J1.1-nectin-1 cells (data not 
agents. To this end, several
e
4Cl and m
and conditions as was described by 
virus was added, and β–gal expression was assayed by X-gal staining or ONPG 6-9 h after 
initiating infection, depending on the virus. The results with each virus varied greatly from 
experiment to experiment, from no inhibition at all on CHO-HVEM and Vero cells, to partial 
inhibition on both cell lines (data not shown). In most instances in which partial inhibition was 
observed on CHO-HVEM cells, some inhibition, although to a lesser degree, was also evident on 
Vero cells.  
Given the variability observed with NH4Cl and monensin, the repertoire of 
lysosomotropic agents was expanded to include the specific vacuolar ATPase inhibitors 
bafilomycin A1 and concanamycin A, and the weak base chloroquine, which prevents endosomal 
acidification by buffering the endosomal pH. Bafilomycin A1 yielded results that were similar to 
those obtained with NH4Cl and monensin, and a high concentration of 400 nM was required to 
achieve even partial inhibition. Concanamycin A and c
th
e reprod
nectin
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 shown). In contrast, endocytic entry of VSV (111) was easily confirmed using the same drugs, as 
illustrated by representative data in Figure 27. In these experiments, CHO-HVEM and J1.1-
nectin-1 cells were pre-incubated with drugs for 30 min and infected with green fluorescent 
protein (GFP)-expressing VSV at an MOI of 1 in the continued presence of drugs for 1 h. Entry 
was detected at 7 hpi. Our results showed that VSV infection was consistently inhibited at low 
concentrations of the different drugs. The lone exception was concanamycin A, which required a 
relatively high concentration (80 nM) to achieve partial inhibition. Thus, in our experience, 
treatment of cells with lysosomotropic agents is a reliable approach to establishing the entry 
pathway of VSV, but not HSV. 
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Figure 27. Effect of lysosomotropic agents on VSV entry into CHO-HVEM and J1.1-nectin-
 cells. 
HO-HVEM (A) and J1.1-nectin-1 (B) cells were pre-incubated with different lysosomotropic 
gents at the indicated concentration for 30 min. The pre-incubation media were then removed 
nd GFP-expressing VSV (MOI=1) was added to the cells along with the previous concentration 
f drug. Cells were incubated at 37ºC for 7 h, and GFP expression was visualized under a 
luorescent microscope. 
1
C
a
a
o
f
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  79
.2 Detection of endocytosed HSV by proteinase protection assay 
 
We next attempted to detect HSV endocytosis by utilizing an approach described by Milne et al. 
(119). This approach is based on the principle that if the entire virus particle is taken up into an 
endocytic vesicle, then viral envelope glycoproteins should be detectable inside the cell shortly 
after the initiation of infection. These internalized glycoproteins should be resistant to protease 
treatment of intact cells, whereas virus fusion at the cell surface should leave the viral 
glycoproteins susceptible to protease digestion. Accordingly, HSV recombinant QOZHG at an 
MOI of 50 was adsorbed to CHO-HVEM cells at 4ºC for 2h, cells were washed to remove 
unbound virus, and either lysed immediately or shifted to 37ºC for 10 or 30 min, and then lysed. 
At the 10 and 30 min time points prior to cell lysis, duplicate samples were treated with trypsin, 
as described earlier (Figure 19), to remove viral glycoproteins exposed at the cell surface as 
either envelope components of intact virus or as a result of envelope fusion with the cytoplasmic 
membrane. Cell lysates were then analyzed by Western blot using antibodies for gB and gD. 
Internalized glycoproteins were not detected (Figure 24, lanes 3 and 5) despite the reportedly 
rapid kinetics (t1/2=9 min) of endocytic HSV uptake by CHO cells (128).  
After binding virus to the cells, we were unable to completely remove all virus particles 
rom the cell surface using trypsin or proteinase K (data not shown). As a consequence, it could 
penetration did occur under our conditions. Thus, neither protease 
rotection nor treatment with lysosomotropic agents provided solid evidence for endocytic HSV 
 CHO cells. Given the discrepancy between our results and published data, these 
7 .2. 
f
not be rigorously demonstrated that virus particles, if not their envelope glycoproteins, had 
indeed penetrated the cells after the different incubations at 37oC. Nevertheless, since it is well 
established that HSV enters cells with a t1/2 of approximately 10 min (78, 91, 128, 171), it may 
be assumed that virus 
p
infection of
 procedures were not used to examine the route of sgD-mediated entry or explore the role of gD 
 HSV endocytosis. in
 
Figure 24. Detection of internalized glycoproteins. 
QOZHG at MOI=50 was adsorbed to CHO-HVEM cells for 2 h at 37ºC. Cells were then washed 
and 5) and then lysed. Duplicate samples of temperature-shifted cells for 10 and 30 minutes were 
analyzed by Western blot. gD was detected with R7 antibody (92) and gB with a pool of  anti-gB 
 
7.2.3. Rate of entry 
   
 
and either lysed immediately (lane 1), or shifted to 37ºC for 10 (lanes 2 and 3) or 30 min (lanes 4 
treated with trypsin (lanes 3 and 5) to allow detection of internalized glycoproteins. Lysates were 
monoclonal antibodies (110). 
 
Our sgD-mediated entry system was used to approach the endocytosis issue from a different 
angle. We reasoned that if gD+ HSV is internalized into CHO cells independently of the gD 
receptor, as proposed by Nicola and colleagues (128), then a gD-deficient virus is likely 
internalized by the same mechanism and at the same rate, whether in the presence or absence of 
sgD. An assay was devised in which the inverse of the rate of virus entry was measured.  In this 
assay, it wasdetermined how much virus remains available at the cell surface for interaction with 
sgD at various times during incubation of attached virus at 37oC. This assay is based on the 
principle that endocytosed gD-deficient virus alone is unable to escape from endosomes and thus 
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 will not express its reporter gene on entry. In contrast, virus that enters upon subsequent addition 
of sgD will be able to reach the nucleus and produce a reporter signal. Thus, the signal that was 
detect would be a measure for the amount of virus that remained at the cell surface at the time of 
sgD addition following incubation of virus-coated cells at 37oC. Since virus binding to GAG+ 
cells is stable at 37oC (see Figure 25), this signal is also an inverse measure for the amount of 
virus internalized prior to the addition of sgD. Using this approach, we sought to confirm the 
conclusion by Nicola et al. (128) that HSV is internalized into CHO cells in a receptor-
independent manner at a t1/2 rate of 9 min. 
gD-deficient virus was attached to CHO-HVEM cells at 4ºC for 2 h, the cells were 
ime, and then sgD was added to allow 
ata suggest a t1/2 of approximately 90 min for sgD- and receptor-
dependent internalization of gD-deficient virus, with the understanding that this number is an 
underestimate if virus dissociation from the cells over this longer period of time is no longer 
negligible. It is possible that the discrepancy between our results and those of Nicola et al. betray 
that gD may have a role in HSV endocytosis that is independent of its receptor-binding role. 
Moreover, it is possible that any of the other glycoproteins that are deleted in our gD-deficient 
recombinant virus (gG, gJ, gI, gE) is important for efficient endocytic uptake. 
 
washed, shifted to 37ºC for various amounts of t
productive infection by virus that remained available at the cell-surface. The results showed that 
there was a very gradual decline over time at 37ºC in the amount of virus that was present at the 
cell surface (Figure 25). Our d
in
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Figure 25. Rate of entry of gD  KΔUs3-8Z in the absence of sgD. 
o that reported for 
wild-type virus (Figure 26). 
- KΔUs3-8Z was adsorbed to CHO-HVEM cells at 4ºC for 2 h. Cells were then washed and 
either sgD was added immediately in 37ºC media, or 37ºC media alone was added for various 
periods of time before adding sgD. Cells were infected for 3 h following the addition of sgD, and 
infection was quantified by ONPG assay 16 h post infection. 
 
 To determine the rate of entry of gD-deficient virus in the presence of sgD, gD-deficient 
virus was bound to CHO-HVEM cells for 2 h at 4ºC, cells were washed, sgD was added and 
cells were shifted to 37ºC to allow infection. At various time points, cells were glycine treated to 
inactivate virus that remained at the cell surface. Infection was measured after 16 h by ONPG 
assay. The results showed that the rate of sgD-mediated entry is comparable t
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Figure 26. Rate of sgD-mediated entry. 
gD- KΔUs3-8Z was adsorbed to CHO-HVEM cells for 2 h at 4ºC, and the cells were washed. 
sgD was added to all wells in 37ºC media, and the cells were glycine treated after various 
amounts of time. Infection was monitored by ONPG assay 16 h post infection. 
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8. DISCUSSION 
 
HSV entry into cells is initiated by the binding of viral envelope components gB and gC to 
glycosaminoglycan moieties on the cell surface. Subsequent binding of viral envelope gD to a 
cell-surface co-receptor, such as HVEM, nectin-1, or 3-OST-3 modified HS, is thought to launch 
a cascade of events promoting fusion of the viral envelope with the cell membrane. The central 
goal of the current study was to establish and characterize a system that could aid in gaining a 
better understanding of the early events in HSV entry. By separating gD from the viral envelope, 
interactions of gD with other viral components involved in HSV entry could potentially be 
identified and studied. The results showed that gD is functional in mediating virus entry as a 
lope-anchorage of gD is not essential for HSV entry. 
ee media at 37ºC 
in the presence or absence of gD-deficient virus, and no evidence was obtained for cellular 
uptake of sgD in the presence of virus. Finally,  sgD-mediated entry did not require cell surface 
GAGs and evidence was obtained that attachment of gD-deficient virus to GAG-deficient cells 
as well as attachment of gD+ virus to GAG- and gD receptor-deficient cells occurred via a novel 
interaction that was less stable than the interaction of either gD+ or gD– virus with cell-surface 
GAGs.  
While this study was in progress, Cocchi and co-workers reported a related set of 
findings (23). In their study, a soluble gD molecule truncated at position 285 was found to be 
active in mediating entry of gD-deficient virus particles into HSV-susceptible cells, whereas 
soluble gD truncated at position 260 was not. Since both of these molecules were previously 
soluble molecule, demonstrating that enve
sgD-mediated entry was less efficient than entry by wild type virus and required sgD recognition 
of a gD cognate receptor. sgD rapidly dissociated from its receptor into sgD-fr
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 shown to bind to the gD receptors HVEM and nectin-1 (93, 159, 190), these results indicated that 
a region between residues 260 and  is munication of gD with the fusion 
achinery. Whether this region is directly involved in interaction with other essential envelope 
than normal infection. Since sgD-mediated infection requires three components, 
compar
285 essential for com
m
glycoproteins is unknown.   
 The experiments described in our study support and extend the findings of Cocchi et al. 
by characterizing sgD-mediated entry into a different target cell line using a different virus strain 
and by defining additional characteristics of the system. Our results extend the published 
findings by demonstrating that gD receptor-deficient CHO cells were resistant to sgD-mediated 
infection. In addition, the receptor specificity of sgD-mediated infection was predictably altered 
by mutations in sgD that selectively abolish binding to nectin-1 (L25P) or HVEM 
(R222N,F223I). Together, these results constituted solid evidence that sgD-mediated infection 
requires a specific binding interaction between the soluble molecule and a cognate receptor.  
 This study further adds to the previous publication by including an estimate of the 
efficiency of sgD-mediated infection. Since gD-deficient HSV is not infectious in the absence of 
sgD and thus can not be titered, an estimate was obtained of the number of virus particles in our 
preparations using quantitative PCR compared to a stock of gD-complemented K∆Us3-8Z of 
known titer. A ratio of HSV genomes:infectious particles was then calculated for each virus. 
Although this procedure does not distinguish between fully and incompletely assembled 
particles, the results suggested that sgD-mediated infection was approximately 10-fold less 
efficient 
ed to two in normal infection, a decrease in efficiency was anticipated. 
 sgD287 was used in our work because this type of truncated gD is known to have a greater 
affinity for HVEM and nectin-1 than the complete ectodomain (93, 159). Cocchi et al. report that 
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 sgD truncated at position 285 (gD285t) is as active in mediating gD-deficient virus entry via 
human nectin-1 as sgD truncated at position 306 (gD306t) (23), suggesting that residues 286-306 
compensate for the reduced receptor-binding activity of the longer molecule by increasing the 
efficiency of a subsequent step in the entry process. 
8.1. Mechanistic Aspects of sgD-Mediated Entry 
In initial experiments, we sought to utilize our system of sgD-mediated infection to clarify the 
CHO-HVEM cells at 37ºC. Entry efficiency was recovered only when sgD and the virus were 
at the cell-surface at the time of the temperature shift to 37ºC. Further investigation suggested 
suggested by Cocchi et al (23), and 2) sgD becomes rapidly unavailable for interaction with 
exclusively in the supernatant of the cells and could not be detected at the cell surface or interior. 
 
 
order in which gD, the HSV virion, and the gD-receptor must interact to effect virus entry. We 
observed that entry was highly impaired when the virus was added subsequent to sgD binding to 
sequentially bound to CHO-HVEM cells at 4ºC, thereby allowing both components to be present 
that receptor-bound sgD was not inactivated instantaneously at 37ºC. These results indicated that 
entry required the immediate presence of cell-attached virus at the time that receptor-bound sgD 
was exposed to the infection temperature. Possible explanations included: 1) sgD must interact 
with the receptor and virion simultaneously in order to perform its fusion-triggering function, as 
subsequently added virus due to dissociation from its receptor, degradation, or internalization. 
Without disproving the first possibility, our results indicated that the second was applicable to 
our experimental conditions. We showed that sgD rapidly dissociated from the cell surface at 
37ºC after excess sgD was removed from the media. After 30 min, sgD was identified 
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 This characteristic was unaltered by the presence of gD-deficient virus during the sgD binding 
step at 4ºC, indicating that cell-associated virus did not stabilize the sgD-cell interaction or 
promote sgD internalization during the subsequent incubation at 37oC.  
Due to the rapid dissociation of sgD from the cell surface in sgD-free media at 37oC, our 
udy could not distinguish whether receptor binding may mediate a stable or transient change in 
sgD that enables communication with gD-deficient virus. Recent evidence supports a model in 
inal portion of the gD ectodomain (residues 260-285) in the free form of gD 
with one of the other essential viral glycoproteins. In the case of soluble gD, it is possible that the 
o
cell-bound sgD is exposed to the infection temperature at the time of virus addition, before 
that infection returned to normal levels when sgD and the virus were sequentially attached to the 
additional information or alternate approaches are required to characterize the active state of 
st
which (i) a C-term
folds over and binds to sequences in the N-terminal region (residues 1-260), and (ii) receptor 
binding dissolves this interaction (50). One suggested scenario is that upon receptor binding, gD 
enters an “open” conformation, enabling a yet to be defined domain of the molecule to interact 
open conformation is unstable in the absence of the remaining viral glycoproteins and enters an 
inactive state in which it is no longer able to interact with gD-deficient virus particles added at a 
later time. This possibility is consistent with our observations that sgD-mediated entry is 
abolished when the soluble molecule is bound to the cells at 37 C prior to virus addition or when 
abundant virus accumulation at the cell surface. Moreover, it is consistent with the observation 
cells prior to raising the temperature. However, proper interpretation of these results is hampered 
by the observed dissociation of sgD from its receptor under our experimental conditions. Thus, 
sgD. 
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 It has previously been reported that approximately 50% of wild type virus adsorbed to 
CHO cells enters the cells within 30 min at 37oC, while the other 50% presumably remains 
attached to the cell surface (128). Following binding of sgD and gD- virus to CHO-HVEM cells 
at low 
8.2. The Role of GAGs in sgD-Mediated and Wild-Type Virus Entry 
ressing nectin-1 were at least as susceptible to sgD-mediated infection as 
GAG-bearing CHO-nectin-1 cells. By comparing the amounts of gD-deficient virus bound to 
temperature, it was therefore expected that a substantial amount of sgD would remain 
stably associated with the cell surface if receptor-bound sgD forms a stable interaction with 
adsorbed virus at 37oC. We did not see evidence for sgD stabilization at the cell surface in the 
presence of virus (Figure 19A). In addition, no evidence was obtained for sgD internalization in 
the presence or absence of virus (Figure 19A). These results argued that either the putative 
interaction between receptor-bound sgD and cell-bound virus was insufficient to retain sgD at 
the cell surface, or that the fraction of virus that fails to enter at 30 min is defective for 
interaction with receptor-bound sgD. Although our observations suggested that sgD was not 
internalized along with the virus, it should be noted that these assays are usually performed at 
much higher levels of infection (119) than attainable using gD-deficient virus combined with 
sgD.  Hence, any endocytic uptake of sgD coincident with virus entry may have escaped 
detection. For future studies, radiolabelled virus can be used to increase the sensitivity of these 
assays. 
 
 
By analogy to wild-type HSV infection, it was anticipated that sgD-mediated infection would be 
enhanced by virus binding to cell-surface GAGs. Surprisingly, we observed that GAG-deficient 
CHO-K1 cells exp
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 pgsA74
745-nectin-1 cells than into their GAG-bearing 
counterparts (Figure 22). 
5-nectin-1 cells in the absence and presence of sgD, evidence was obtained for GAG- 
and sgD-independent virus attachment, suggesting the existence of a previously unknown 
attachment mechanism.  
Interestingly, the ratio of virus bound to GAG-expressing CHO-K1 cells compared to 
GAG-deficient pgsA745 cells appeared significantly higher for KHZ.1 (Figure 24A, lanes 1 and 
3) than for gD-deficient KΔUs3-8Z (Figure 24B, lanes 1 and 2). This observation points to either 
an increased ability of gD- virus to bind to GAG- cells or a reduced ability of gD- virus to bind to 
GAG+ cells, as compared to virus containing the full complement of envelope glycoproteins 
(illustration in Figure 28). One possible model to explain these results is that the novel binding 
function may represent a downstream interaction in the fusion cascade whose formation is 
normally controlled by the gD-receptor interaction (Figure 29). In the absence of gD, binding 
through the novel binding interaction may be more efficient. In any event, the absence of GAGs 
had a smaller effect on gD– virus attachment than on KHZ.1 attachment. Together with the 
substantially higher levels of nectin-1 on our pgsA745-nectin-1 line compared to CHO-nectin-1 
cells (Figure 21), we believe that this may explain the counterintuitive observation of greater 
sgD-mediated entry into the GAG-deficient pgsA
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Figure 28. Model illustrating possible higher binding effeciency of gD- virus through novel 
ptor (2), gD may release gB (3), allowing gB to enter a 
 is now able to bind to its coreceptor (4). (B) In an HSV virion which 
lacks gD in its evelope, gB is not bound by gD (1), and is free to interact with its receptor (2). 
 
In spite of the ability of our gD-deficient virus to bind to GAG-deficient cells, no entry 
was detected when the virus was pre-adsorbed at 37ºC or 4ºC, the cells were washed, sgD was 
added, and the cells were shifted to 37ºC for a 3 hour infection period (Figure 25C and D). For 
comparison, normal levels of entry were observed when GAG-positive CHO-HVEM cells were 
tested by the same protocol (Figure 15D). Thus the stability of HSV binding through the novel 
binding interaction.  
(A) In an HSV virion containing a full complement of envelope glycoproteins, gD may interact 
with gB, holding it in a conformation in which gB is unable to interact with its coreceptor (1). 
Upon binding to a cell-surface rece
conformation in which gB
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 binding interaction with HSV bound through GAGs was compared. Our results indicated that 
both “wild-type” (KHZ.1) and gD-deficient virus dissociated from GAG-deficient cells during 
incubation of  10-30 min at 37ºC, while no dissociation was detected for either virus from GAG-
expressing cells (Figure 26). These observations demonstrated that the novel binding interaction 
does not attach HSV to cells as stably as GAGs. Thus it is likely that gD-deficient HSV pre-
incubated with GAG-deficient pgsA745-nectin-1 cells dissociates from the cells before the 
subsequently added sgD is able to attach to its receptor and trigger fusion. 
Although the significance of the novel attachment function under normal conditions is 
not known, it is conceivable that it represents an essential co-receptor or plays a prominent role 
in virus attachment to GAG-deficient cells. In support of this notion, Bender et al. have obtained 
evidence for a novel binding function of gB and have linked this function to the fusion process 
by demonstrating that soluble gB blocks virus infection of GAG-deficient cells (5). Although it 
remains to be seen whether the interaction we observe involves gB, this is a likely possibility. 
Future studies will be designed to investigate this possibility by using a gB- virus in our assays. 
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8.3. Endocytosis 
 
In light of recent evidence suggesting that HSV entry into certain cell types occurs through 
endocytosis and not fusion at the cell-surface, we sought to define the pathway of sgD-mediated 
entry in order to determine whether this system could be used to study the role of gD in 
endocytosis. Our use of lysosomotropic agents to confirm endocytic entry of gD+ HSV into 
receptor-bearing CHO but not Vero cells yielded inconsistent results that did not support 
published observations (119, 126, 128). In contrast, all of the drugs that were tested consistently 
inhibited entry of a control virus, VSV, whose entry pathway is well established to be mediated 
by endocytosis. Complete inhibition of VSV infection was observed at low concentrations of 
these drugs, with the exception of concanamycin A which required a higher concentration than 
commonly used.  
Nicola and co-workers used several reliable methods to demonstrate that entire HSV 
particles are internalized into CHO cells (126, 128). Indeed, endocytic HSV internalization that 
does not lead to productive infection has previously been documented (12, 199). The main 
evidence presented by Nicola et al. for productive infection by endocytosed HSV was their 
observation that infection was inhibited by various agents that inhibit the acidification of the 
endocytic vesicles or prevent endocytic uptake from the cell-membrane. In the hands of Nicola et 
al., these drugs completely inhibited HSV entry into CHO cells without negative effects on entry 
into Vero cells, whose HSV entry pathway has been firmly established to be fusion at the cell 
surface (47, 48, 122). In our hands, when a certain drug was observed to inhibit infection of 
CHO cells to a significant degree, inhibition was also observed on Vero cells, although to a 
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 somewhat lesser degree. Based on this experience, we feel that it can not be concluded that 
cytosis and into the other through fusion at the 
cell surface. In support of this notion, no evidence was presented by Nicola et al. showing virions 
fusing with endocytic vesicles in their EM study, while virions fusing at the cytoplasmic 
membrane were readily observed with Vero cells (182). As mentioned in the introduction, the 
use of endocytosis inhibiting drugs is not considered to be an ideal method to determine whether 
endocytosis leads to productive infection of a virus, since most of these drugs have non-specific 
effects on the cell. While we accept the finding that HSV can be endocytosed by CHO cells, we 
suggest that the verdict is still out whether this pathway leads to productive infection.   
An alternative possibility is that productive infection of CHO cells can occur via multiple 
pathways. HSV is a large and complex virus that utilizes redundant mechanisms to accomplish 
many tasks. In their study, Nicola et al. used CHO cells that are stably transformed with the lacZ 
gene under control of the HSV ICP4 promoter, and a virus that is slightly different from the ones 
used in our study. The balance between endocytosis and fusion at the cell membrane may be 
quite sensitive in the case of HSV, and use of a slightly different cell line and virus strain may tip 
the balance one way or the other.  
 We attempted to obtain evidence for HSV endocytosis by examining protection of 
envelope glycoproteins from trypsin digestion at early stages of infection (Figure 24). This assay 
was based on the principle that if a complete virus particle is internalized into an endocytic 
vesicle, the glycoproteins will be protected from external enzyme digestion. Our results clearly 
showed that gB and gD were not internalized in our cells (Figure 24), suggesting that enveloped 
particles were not endocytosed in our system. Although rapid HSV internalization has been 
demonstrated in many studies (78, 91, 128, 171), we were unable to directly demonstrate that 
productive entry into one cell type is through endo
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 virus particles were indeed internalized in some form at 10 or 30 min after the initiation of 
infection. This was due to incomplete protease sensitivity of virus attached to the cell surface to 
removal by trypsin or proteinase K. Thus, although protease-resistant VP5 was observed after 
incubation of virus-coated cells for 10-30 min at 37oC, it could not be concluded with certainty 
whether any fraction of this signal represented internalized virus. Additional experiments are 
required to optimize the conditions in order to conclude that entire glycoprotein-bearing virus 
particles are not found inside the cells in our system. 
 Finally, we took advantage of our sgD-mediated entry system to explore the reported 
receptor-independent endocytic internalization of HSV into CHO cells (128). We reasoned that if 
50% of
ytosis. 
 infectious virus is internalized after 9 min in a receptor-independent manner, but can not 
escape from the endosomal compartment in the absence of a gD receptor (128), then productive 
sgD-mediated infection should be drastically reduced by prior incubation of cell-attached virus at 
37ºC. In other words, 50% of pre-attached virus should be endocytosed after 9 min at 37oC and 
thus be unavailable to sgD added at that time to mediate productive infection. This assay showed 
that the rate of virus removal from the cell surface was at least 10-fold slower than the reported 
rate of receptor-independent endoc
 Several explanations exist for this result. One that is consistent with the results that were 
obtained with the other methods that we attempted to use to address the endocytosis question, is 
that infectious virus does not enter our cells by endocytosis, and simply dissociates slowly over 
time. Another possibility is that by measuring the amount of virus left at the cell surface at each 
time point instead of the amount of virus that has already entered the cell, our assay does not 
truly represent the rate of internalization. Addition of sgD at the various time points could 
stimulate entry of additional virus that would not have entered the cell initially. A third 
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 possibility that requires further investigation is that the rate of endocytosis in the absence of sgD 
is reduced.  This would be interesting, since Nicola et al. reported that the rate of endocytosis 
does not depend on the presence of a gD-receptor.  
 The least invasive method to conclusively show which pathway is taken by productively 
infecting virus is real-time microscopy, which can be used to follow virus particles whose 
capsids and/or envelopes have been fluorescently labeled (95, 164). In addition, dominant-
negative mutants which interfere with clathrin-mediated endocytosis can be used, such as 
ps15ΔE 95/295 or DynK44A (6, 15). These methods should prove useful in the future to settle the 
ongoing dispute over the pathway of HSV-1 entry. 
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8.4.  SUMMARY 
 
interactions occurring during the earliest stages of HSV infection. In this study, we demonstrated 
we showed that sgD-mediated entry is neither dependent on nor enhanced by the presence of 
 cell-attachment of our gD-deficient virus 
was enhanced by these cellular structures. Thus, our findings raise the possibility that GAGs, 
while promoting attachment, may negatively affect the entry process. We extended these 
observations by showing that HSV can utilize a previously unknown interaction for gD- and 
GAG-independent attachment to cells. Identification of the viral and cellular components of this 
novel interaction, as well as definition of the role of this interaction in normal HSV infection, are 
among the future goals derived from this study.  
Characterization of a system in which HSV-1 glycoprotein D provided in trans was shown to 
mediate entry of gD-deficient virions offers new opportunities to dissect the molecular 
that sgD-mediated entry requires direct interaction of sgD with a gD cognate receptor. Moreover, 
GAGs on the cell surface, although we confirmed that
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